854.568

⑫ **EUROPEAN PATENT APPLICATION**

㉑ Application number: 80300692.3

㉒ Date of filing: 06.03.80

�51 Int. Cl.³: **C 07 G 7/00, C 12 P 21/00,
G 01 N 33/54, A 61 K 49/00
// A61K39/00, C12N5/00**

�covolapplicant⁷¹ Applicant: Bogoch, Samuel, Dr., 46 East 91st Street, New
York, New York 10028 (US)

㉟⁷² Inventor: Bogoch, Samuel, Dr., 46 East 91st Street, New
York, New York 10028 (US)

㉞⁷⁴ Representative: Laredo, Jack Joseph et al, Elkington and
Fife High Holborn House 52/54 High Holborn, London,
WC1V 6SH (GB)

㊴ Recognins, their chemoreciprocals, target attaching globulins and processes for producing these products; methods of
detecting cancer tumors.

㊗ Disclosed herein are novel compounds Recognins
termed Recognin M and Recognin L, belonging to a group
of compounds termed Recognins, and produced, respec-
tively, from artificial mammary and lymphoma cancer cells.
Recognin M and Recognin L are useful for therapeutic and
diagnostic purposes. They are each characterized by form-
ing a single line precipitate with a specific antibody in
quantitative precipitation tests and Ouchterlony gel diffu-
sion tests; by being soluble in water and aqueous solutions
having an acid or neutral pH, and insoluble at an alkaline
pH; having a spectrophotometric absorption peak wave-
length of 280 mµ; and having a molecular weight of about
8,000 (as determined by thin layer gel chromatography).
Recognin M contains approximately 90 and Recognin L
approximately 92 aminoacid residues.

EP 0 015 755 A2

TITLE

RECOGNINS M AND L AND THEIR CHEMORECIPROCALS

This invention is directed to a group of compounds,
herein termed Recognins. Recognins are made by treat-
ing normal or tumour cells or artificial cancer cells,
and separating the desired products. The Recognins may
5 be used to prepare their Chemoreciprocals, i.e., by
contacting with body fluids unsupported Recognins or
the Recognins on a support. These Chemoreciprocals
are useful for diagnostic and therapeutic purposes,
i.e., for diagnosing and treating cancers. The
10 Chemoreciprocals are substances which react with
immunochemical-like specificity with a Recognin in vivo
or in vitro, e.g., in a quantitative precipitin test,
in Ouchterlony double diffusion or in immunofluorescence.
Recognins and their Chemoreciprocals as novel
15 groups of compounds were first referred to in my U.S.
Application Serial No. 941,940, filed September 13,
1978; which in turn was a continuation of my U.S.
Application Serial No. 852,200, filed November 17, 1977;
which in turn was a continuation of my U.S. Application
20 Serial No. 621,112, filed October 9, 1975, which in
turn was a Continuation-in-Part of each of my U.S.
Applications Serial Number 553,075, filed February 25, 1975;
Serial Number 550,432, filed February 18, 1975; Serial
Number 450,404, filed March 12, 1974; and Serial Number
25 385,451 filed August 3, 1973; and also a continuation-
in-part of my U.S. Application Serial No. 922,799, filed
July 7, 1978. Reference should also be made to my
U.K. Patents Nos. 1,524,221 and 1,532,803 and also to
my U.K. Patent No. 1,533,464 (which claimed priority from

the above-noted U.S. Applications Serial Nos. 550,432;
553,075; and 621,112). Furthermore, reference should
be made to my copending European Application No.
79 301315.2, filed on July 6, 1979 (claiming priority
5   from the above-noted U.S. Applications Serial Nos.
922,799 and 941,940.

One of the Recognins is Astrocytin. Astrocytin is
produced from brain tumour tissue, preferably brain
glioma tumour tissue. Protein fractions containing
10 the Astrocytin precursor are first extracted from
the tissue. A preferred method of accomplishing
the extraction is to treat the tissue with a neutral
buffer under conditions of homogenization or other
techniques to disrupt the cells and tissues in order
15 to solubilize protein fractions which contain the
Astrocytin precursor.

At this point, the Astrocytin precursor is still
bound to many large moleculr weight substances including
proteins, glyco-proteins, lipoproteins, nucleic acids,
20 nucleoproteins, and so on. The solublized proteins are
separated from the resulting tissue extract. The
extract solution from the tissue is clarified to remove
insoluble particals. The low molecular weight contaminants
are removed from the resulting solution, by a per-
25 evaporation concentration technique. The solution which
is obtained is then treated to cleave Astrocytin precursor
from other contaminants in order to obtain the protein
fraction having a pK range between within the range of
from about 1 to 4, inclusive. Thus, for example, the
30 solution is placed on a chromatographic column and eluted
with increasingly acidic solvents. All of the fractions
which are eluted in the neutral or acid range down to
pK 4 are discarded, and those fractions with the pK
range 1-4 are collected. The eluate is then treated to
35 obtain a product having a molecular weight of about

8,000 (TLGC). TLGC = thin layer gel chromatography = method for determining molecular weight unless otherwise specified. The treatment is accomplished, for example, by first filtering the material to remove low molecular

5   weight substances, i.e., those of molecular weight below 1,000, and filtering again to remove those of molecular weight above 25,000. The fraction having a molecular weight between 1,000 and 25,000 is then further treated, i.e., by thin layer gel (TLG) chromatography, to obtain

10   Astrocytin.

     Thus, Astrocytin may be produced by extracting brain glioma tumor tissue with a neutral buffer, by repeated homogenization and high speed centrifuging, separating from the resulting extract the fraction having a pK

15   value within the range of from about 1 to 4, separating from said fraction the substances having a high molecular weight, i.e., up to about 230,000, and isolating therefrom the product Astrocytin having a molecular weight of about 8,000.

20   The product Astrocytin prepared in accordance with this process is characterized by forming a single line precipitate with its specific antibody in quantitative precipitin tests and Ouchterlony gel diffusion tests, being soluble in water and aqueous solutions having

25   an acid or neutral pH, and insoluble at an alkaline pH, having a spectophotometric absorption peak wavelength of 280 mμ and having a molecular weight of about 8,000.

     Astrocytin is also characterized by having a very

30   high percentage of residues of glutamic acid and aspartic acid and a very high ratio of these acids to histidine. A further analysis of Astrocytin is provided below.

     In a manner similar to that described above, another Recognin, called Malignin, is produced from artificial

35

cancer cells, i.e., cancer cells grown by _in vitro_ fermentation. Malignin has a molecular weight of about 10,000 and similar but distinct aminoacid residue composition to Astrocytin, i.e., high ratios of

5 glutamic acid and aspartic acid and high ratios of these acids to histidine. A further analysis of Malignin is provided below.

Thus, Malignin can be produced by extracting artificial brain glioma cancer cells grown in a

10 fermentation culture with a neutral buffer by repeated homogenization and high speed centrifuging, separating from the resulting extract the fraction having a pK range of about 1 to 4, separating from said fraction the substances having a high molecular weight, i.e.

15 up to about 230,000, and isolating therefrom the product having a molecular weight of about 10,000.

The amount of Malignin produced in artificial cell fermentation and the percentage of total protein produced in artificial cell fermentation which is Malignin can

20 be increased by the growth of an artificial cancer cell culture in large size growth containers.

Malignin prepared in accordance with this process is characterized by forming a single line precipitate with its specific antibody in quantitative precipitin tests

25 and Ouchterlony gel diffusion tests, being soluble in water and aqueous solutions having an acid or neutral pH, and insoluble at an alkaline pH, having a spectro-photometric absorption peak wave-length of 280 mμ and having a molecular weight of about 10,000.

30 In a manner similar to that described above, another Recognin, called Recognin M, is produced from artificial mammary cancer cells, i.e., mammary cancer cells grown by _in vitro_ fermentation. Recognin M has a molecular weight of about 8,000 and similar but distinct

35 aminoacid residue composition to Astrocytin and Malignin,

i.e., high ratios of glutamic acid and aspartic acid and high ratios of these acids to histidine. The principal differences in composition between Malignin and Recognin M are that the latter has decreased amounts

5   of aspartic acid, glutamic acid, leucine and tryosine and increased amounts of proline, glycine and alanine, A further analysis of Recognin M is provided below.

Recognin M can be produced by extracting artificial mammary cancer cells grown in fermentation culture with

10   a neutral buffer by repeated homogenization and high speed centrifuging, separating from the resulting extract the fraction having a pK range of about 1 to 4, separating from said fraction the substances having a high molecular weight, i.e., up to about 230,000, and

15   isolating therefrom the product having a molecular weight of about 8,000.

Recognin M prepared in accordance with this process is characterized by forming a single line precipitate with its specific antibody in quantitative precipitin tests

20   and Ouchterlony gel diffusion tests, being soluble in water and aqueous solutions having an acid or neutral pH, and insoluble at an alkaline pH, having a spectrophotometric absorption peak wave-length of 280 mμ and having a molecular weight of about 8,000.

25   In a manner similar to that described above, another Recognin, called Recognin L, is produced from artificial lymphoma cancer cells, i.e., lymphoma cancer cells grown by in vitro fermentation. Recognin L has a molecular weight of about 8,000 and similar but

30   distinct aminoacid residue composition to Astrocytin, Malignin and Recognin M, i.e., high ratios of glutamic acid and aspartic acid and high ratios of these acids to histidine. As compared with Malignin, Recognin L has decreased amounts of aspartic acid, glutamic acid,

35   leucine and tryosine and decreased amounts of proline, glycine and alanine. A further analysis of Recognin L

is provided below.

Thus, Recognin L can be produced by extracting
artificial lymphoma cancer cells grown in fermentation
culture with a neutral buffer by repeated homogenization
and high speed centrifuging, separating from the
resulting extract the fraction having a pK range of
about 1 to 4, separating from said fraction the
substances having a high molecular weight, i.e., up to
about 230,000, and isolating therefrom the product
having a molecular weight of about 8,000.

Recognin L prepared in accordance with this
process is characterized by forming a single line
precipitate with its specific antibody in quantitative
precipitin tests and Ouchterlony gel diffusion tests,
being soluble in water and aqueous solutions having an
acid or neutral pH, and insoluble at an alkaline pH,
having a spectrophotometric absorption peak wave length
of 280 mμ and having a molecular weight of about 8,000.

Recognins are further characterized by being
capable of complexing with bromoacetylcellulose to form
bromoacetylcellulose-Recognin and producing the specific
Anti-Recognin antibodies upon injection into mammals,
the Anti-Recognin attaching specifically to the Recognin-
precursor _in situ_. For example, one Anti-Recognin,
Anti-Malignin is toxic to brain tumour cells _in vitro_.

Recognins, such as Astrocytin, Malignin, Recognin M
and Recognin L and similar substances are useful as
products which may be introduced into a biological
system to reduce foreign reactions, such as by coating
a material with a Recognin. A further example may be to
introduce a Recognin in order to produce the Chemo-
reciprocals in the biological system. They may also be
used nutritionally to encourage the growth of a particular
biological system of which they are a part. A further
utility of Recognin is the production of Target reagents

which comprise the complexes of the Recognin with a
carrier to facilitate its applicability in biological
systems.   Thus, for example, the complex conveys the
physio—chemical characteristics of the Recognin itself.
5   The carrier should be selected from those which form
a complex with the Recognin and which are substantially
biologically inert.

Any substance known in the art which will form a
stable complex with polypeptides or proteins may be
10   useful for complexing with the Recognin. An example is
a cellulose-based material, such a bromoacetyl—cellulose.
In addition to being inert to the biological system, the
carrier should he one which does not alter the specific
physio—chemical properties of the Recognin which are
15   useful for the purposes set forth herein.

The complexes of the Recognin and its carrier are
useful for producing, separating and identifying its
chemoreciprocal in any biological system with which
it is brought into contact. The Recognin—carrier
20   complex is also useful for stimulating the production
of its chemoreciprocal precursor in any biological
system into which it is introduced.

One class of Chemoreciprocals are the anti—Recognins,
i.e., anti—Astrocytin, anti—Malignin, anti—Recognin M
25   and anti—Recognin L. These may be made by injecting the
Recognin into a biological system. An immunologically
effective dose of Recognin is brought into contact with
body tissues or fluids in a manner which induces an
antibody response in accordance with techniques known
30   in the art for producing antibodies. The anti—Recognins
may be used for the delivery of materials such as
diagnostic, nutritional and therapeutic agents to specific
cells or sites in a biological system; this comprises
introducing said agent in complexed form with the
anti—Recognin into the biological system. The anti—
35.   Recognin are also useful for diagnosing the presence of

tumour cells in a histology section, by applying the
Anti-Recognin conjugated with a labelling substance
such as a dye or radioactive substance, to said section,
whereby staining or radioactive labelling occurs only with

5   the tumour cells. Yet another use for anti-Recognins
is to increase the yield of other useful Chemoreciprocal
products (such as TAG, described below) from a mammal;
this comprises injecting an immunologically effective
dose of a Recognin into the mammal, or other biological

10   system.
      Prior to the present invention, glycoprotein
complexes were prepared from brain tissue and caused
to yield antibodies. Thus, separated materials known
as 10B glycoproteins produced from Tay-Sachs's disease

15   brain tissue, were injected into rabbits and antibodies
produced. These Tay-Sachs antibodies were used in the
immunofluorescent study of brain-containing tumours:
only reactive, normal non-tumour glia, not tumour glia,
were stained by these antibodies.

20   In contrast, when Astrocytin was produced from
tumour tissue, and antibodies to Astrocytin (Anti-
Astrocytin) were produced and employed in immunofluorescent
studies of the brain, only tumour glia, not normal
(non-tumour) glia, were stained by Anti-Astrocytin.

25   Thus, the tissue of origin and the nature of the anti-
bodies, as well as the specific type of cells stained
show that anti-Tay-Sachs antibodies and anti-Astrocytin
are clearly different products.
      Another class of Chemoreciprocals is Target reagents

30   complexed with their chemoreciprocals. For example,
Astrocytin Target (the product of Astrocytin complexed
with a carrier such as bromoacetylcellulose) is brought
into contact with anti-Astrocytin. This type of compound
may be coupled with, and used for, the delivery of

35   diagnostic, nutritional and therapeutic agents to

specific cells or sites in a biological system. These compounds may also be used for purification procedures. For example, Anti-Astrocytin may be made by the decomplexing of Bromoacetylcellulose-Astrocytin-Anti-Astrocytin by hydrolytic treatment with an acid or proteinase enzyme. Target reagents are also useful in increasing the amount of TAG products (described below) in a biological system, e.g. by bringing an immunologically effective dose of Target into contact with the body tissues of fluids.

Additional Chemoreciprocals are TAG reagents (i.e., Target-Attaching Globulins). The TAG products are produced by bringing Target reagents into contact with body fluids for varying periods of time to form a complex and cleaving TAG therefrom. Two useful embodiments are S-TAG and F-TAG.

A process for producing S-TAG (Slow-Target-Attaching-Globulin) comprises reacting blood serum or other body fluid with Target (e.g., Bromoacetylcellulose-Malignin, Bromoacetylcellulose-Recognin M and Bromacetyl-cellulose-Recognin L) for approximately two hours or more at a low temperature, e.g., at about 4°C, and cleaving S-TAG from the resulting material, e.g., with dilute acid for approximately two hours at a temperature of about 37°C. The product S-TAG prepared in accordance with this process is characterized by being soluble in aqueous buffered solutions, forming a single line precipitate with its corresponding Recognin in Ouchterlony gel diffusion tests, being non-dialysable in cellophane membranes, being retained by millipore filters which retain molecules of over 25,000 molecular weight, having molecular weights in different states of aggregation, as determined by thin layer gel chromatography, of approximately 50,000, and multiples thereof into the macroglobulin range, and having a spectrophotometer

absorbtion peak wave-length of 280 mµ.

A process for producing F-TAG (Fast-Target-
Attaching-Globulin) comprises reacting blood serum or
other body fluid with Target (e.g., Bromoacetylcellulose-
5   Malignin, Bromoacetylcellulose-Recognin L or Broma-
cetylcellulose Recognin M) for approximately 10 minutes
at a low temperature, e.g. at about 4°C, and cleaving
F-TAG from the resulting material, e.g. with a dilute
acid for approximately two hours at a temperature of
10   about 37°C. The product F-TAG prepared in accordance
with this process is characterized by being soluble
in aqueous-buffered solutions, forming a single line
precipitate with its corresponsing Recognin in Ouchterlony
gel diffusion tests, being non-dialysable in cellophane
15   membranes, being retained by millipore filters which
retain molecules of over 25,000 molecular weight, having
molecular weights in different states of aggreagation
as determined by thin layer gel chromatography of
approximately 50,008, and multiples thereof into the
20   macroglobulin range, and having a spectrophotometer
absorption peak wave-length of 280 mµ.

TAG products are useful for detecting cancer
tumours in living mammals by determining the concentration
of S-TAG and F-TAG produced by a known volume of the
mammal's blood serum or other body fluid, and correlating
25   this concentration with amounts determined to be
indicative of cancer. TAG products are also useful
for diagnosing the presence of tumour cells in a histology
section, which comprises applying TAG conjugated with
a labelling substance such as a dye or radioactive
30   substance, to said section, whereby staining or
radio-active labelling occurs only with the tumour
cells. TAG products additionally have been found to be
cytotoxic to tumour cells. TAG products are also useful
for directing the delivery of diagnostic, nutritional
35

and therapeutic agents to specific cells or sites by introducing said agents in complexed form with the TAG product.

5   Normal cell division in plants or animals is restricted or inhibited when the cells come to occupy fully a particular space. The mechanisms (a) by which normal cells "recognize" that they have filled the space available to them, and (b) by which the operation of this recognition mechanism in turn inhibits cell division,

10   have both been unknown. A group of compounds have now been produced whose precursors are increased in concentration when normal recognition and learning occur, and which relate to recognition and learning in particles and cells, and with the connection of cells to each other.

15   These compounds are termed RECOGNINS. Attempts to produce these compounds from normal cancer cells showed that they are absent as such, and that changes in their molecular structure have occurred at the same time as the cancer cells have lost their ability (a) to

20   recognize that they have filled their normal volume, and/or (b) to stop dividing when they have filled their normal volume.

      Novel compounds and methods for producing such compounds have been discovered. These new compounds

25   are termed RECOGNINS. RECOGNINS are novel compounds which have physiochemical characteristics which mimic those configurations characteristic of cancer cells in terms of their failure to recognize and to stop cell division. The use of RECOGNINS goes beyond insight into

30   the cancer mechanism, for immediate products and methods are thereby provided which are useful in the diagnosis and treatment of cancer, and for its prevention.

      Methods by which artificially cultered cells can be

35   used to produce Recognins have been discovered. One

advantage of the methods disclosed herein is that Recognins and new products from them can now be manufactured efficiently in virtually limitless quantities.

This invention transcends the field of cancer

5 research and is immediately applicable to any and all biological systems in which it is desired to influence all growth and metabolism. Thus, by the manufacture of the particular compound or compounds of appropriate cell type in artificial culture, and the further manufacture

10 of products from these substances, specific influence may for the first time be brought to bear on any tissue, cell, cell organelle, sub-organelle molecule or molecular aggregate in any living system. Thus, specific nutritional influences at critical times in development,

15 specific diagnostic, preventative and treatment methods, and in the construction of an artificial bioelectrical system (as in tissue or organ transplants) can all be effected for the first time. These artificial bioelectrical system can now be made to bear the

20 characteristics of the specific RECOGNIN, eg MALIGNIN, RECOGNIN L or RECOGNIN M, or their CHEMORECIPROCALS of the normal tissue or component which they will neighbour and thus be "recognized" as "foreign", thereby avoiding the usual reactions to

25 alien substances, including rejection.

Another aspect of this invention is the production of a valuable specific antibody-like product (Anti-Astrocytin) relative to a specific brain product (Astrocytin), permitting the use of this antibody-like

30 product specifically to complex with, and, as a specific delivery vehicle to, specific points in the nervous system of all species. MALIGNIN, ASTROCYTIN, RECOGNIN M and RECOGNIN L are all RECOGNINS.

Still another aspect of this invention is the pro-

35 duction from biological fluids of two new products,

TARGET-ATTACHING-GLOBULINS (TAG), which are so named
because they are produced by two reactions, the first
the reaction of biological fluids with a synthetic
complex containing physiochemical configurations which
5   mimic those of the MALIGNIN, RECOGNIN L and RECOGNIN M
and called TARGET, the second the cleavage of the
specific TAG from the complex, and by the measure of the
TAG so produced obtaining a quantitative indication from
the biological fluids of living organisms as to
10 whether there is present a tumour in that organism;
hence, a diagnostic test for tumours. Because TAG
products and ANTI-MALIGNIN are physiochemically
complementary to MALIGNIN, they are termed
CHEMORECIPROCALS.

15   I have further discovered that two quantitatively
and qualitatively distinct TAG products can be produced
depending upon the time permitted for the reaction of
serum with the specific TARGET reagent used, and
depending upon the time permitted for the cleavage
20 of the product which has been complexed.
        After examining the amounts of these products which
could be produced from a number of different individuals
with brain tumours and various other medical disorders,
as well as in those with no apparent disease process,
25 it became apparent that the amounts of those two new
products which could be produced in a given individual
were indicative of whether that individual had a brain
tumour, and hence, a novel serum diagnostic
test for brain tumours had been discovered.
30   The utility of these new products, in addition to
their use in the diagnosis from serum and other biological
fluids of the presence of brain and other tumours, is
illustrated by the demonstration that TAG and anti-
RECOGNIN compounds attach to glial tumour cells
preferentially in histological section of brain tumour
35 and surrounding tissue removed upon surgery of the
brain tumour. This preferential labelling by TAG and

Anti-RECOGNINS of tumour cells is demonstrated through
standard immunofluorescent techniques. Thus, a new
method is also available for determining through
histological examination with a new degree of

5 certainty whether tumour cells have penetrated to the
very edges of the tissue removed indicating the
likelihood that tumour still remains in the brain
or other organ, or that tumour cells are absent from
the periphery of the tissue removed, indicating the

10 possibility that all of the tumour has been removed
from the brain or other organ. In addition, the TAG
and Anti-RECOGNINS produced as described have been found
to be cytotoxic in relation to glioma brain tumour cells
grown in tissue culture $\underline{in}$ $\underline{vitro}$. This high affinity

15 for tumour cells in another medium, here grown in tissue
culture, is further evidence of the specific-coupling
potential of the new TAG products, and explains the
adoption of the name TARGET-ATTACHING-GLOBULINS
(TAG) as do the properties of TAG in relation to the

20 synthetic product TARGET, and to tumour cells in
histological section. Further, the cytotoxicity of TAG
and anti-RECOGNINS in relation to tumour cells
provides an additional new diagnostic test for the
serum of patients who are suspected of suffering from

25 a tumour. Thus, for example, the serum or other body
fluid of these patients is reacted with TARGET to produce
TAG, and the product TAG is tested in tissue culture
growths of tumour cells for cytoxicity. Both the
concentration of TAG and the degree of cytoxocity

30 manifested by the TAG which can be produced from a given
individual's serum may be not only diagnostic but also
of value in tracing the course of the disorder pre-
operatively and post-operatively in a given patient.
The coupling of radioactive and dye tracers to TAG

35 provides new TAG products which are useful $\underline{in}$ $\underline{vivo}$ in

the diagnosis of tumours and in their exact localization.
Thus, e.g., the injection of suitably labelled TAG
either intra-arterially or intravenously, into the
cerebrospinal fluid, or directly into the brain tissue

5   or its cavities, permits the demonstration by radioactive
means, or by visualization of the coupled dye, of the
presence of a brain tumour, for it is only to the tumour
cells that the TAG specifically attaches. Further,
this method permits the precise visualization of the

10   location of the brain tumour. This can be seen to
be an improvement of the in vivo diagnostic method using
anti-ASTROCYTIN produced in rabbit blood to label the
brain tumour, bec se the use of TAG produced from
human serum avoids the possibility of foreign protein

15   reactions. Since TAG and anti-RECOGNINS have the chemical
specificity which permits preferential attachement
to ASTROCYTIN precursor containing tumour cells both
in vitro and in vivo, these products may also be used
therapeutically, as well as diagnostically, when

20   coupled, e.g., with radioactive, proton capture agents,
or other toxic physical or chemical agents, so that
these toxic substances may be localized preferantially
through these compounds' specificity of attachement in
the tumour cells as compared with their neigh

25   normal cells. This selectivity is universally
recognized as the crucial, or at least one crucial
factor for achieving effective chemical or physical
therapy of tumours, and a factor which has hitherto
not been achieved. Thus, TAG has demonstrated efficacy

30   in attaching preferantially to the tumour cells, and
should have promise as a new therapeutic product for
these reasons.

          In the serum of patients with malignant tumours,
as will be seen in the examples below, one type of
TAG, SLOW-TAG (S-TAG) as distinguished from FAST-TAG

35

(F-TAG), can be produced in relatively greater amounts from a given volume of serum than in patients without such tumours. This suggests that either one of TAG'S naturally occuring precursors (P-TAG)

5 is increased in concentration or that other factors exist which favour the relative in vitro production of S-TAG over F-TAG.

The possible relationship of the function of the actual synthetic products TARGET and TAG to their

10 precursors, and in turn of the functions to them of postulated but not demonstrated cell "antigens" and circulating "antibodies" which may exist in vivo, has yet to be elucidated. Thus, for example, in antibody-like fashion, F-TAG and S-TAG produce single

15 discrete lines of reaction with ASTROCYTIN in Ouchterlony gel diffusion, and the injection of TARGET into rabbits induces an increase in the yield of TAG products from rabbit serum after reaction with TARGET. The finding that there may be a normal level of a precursor

20 resembling antibody to a cell antigen which is hidden in the non-dividing cell raises a question as to the possible function of the pair. It is here proposed that TAG precursor (P-TAG) and TARGET-like substances exist in vivo and function in the control of cell proliferation

25 and cell death. Thus, for example, the exposure of a cell constituent which normally is not directly exposed to serum proteins may occur during cell division. The exposure of this cell constituent could result in that constituent becoming converted to a TARGET-like substance

30 to which the attachment of a P-TAG-like molecule from serum may then occur, which would stimulate cell division or inhibit it. Alternatively, a non-dividing cell which is injured or malfunctioning may expose a TARGET-like substance to which the attachment of P-

35 TAG-like molecules may be reparative. However, under certain cell conditions, the attachement of P-TAG-like

-17-

molecules may induce the destruction of the cell (e.g.,
ANTI-GLIOMA-TAG synthetically produced as here
described is markedly cytotoxic to glioma tumour
cells growing in tissue culture). This could thus
represent a mirror of a normal mechanism for the control
of cell division, and for either the repair or the
removal of individual cells in the body throughout
the life of the organism. If the exposure of cell
constituents is abnormally increased so that abnormally
large amounts of cell TARGET-like substances are
formed, as may occur in rapidly dividing cancer cells
such as in brain gliomas, an increase in the concentration
of one type of serum P-TAG relative to another may be
induced.

Whatever the actual function of the precursors, the
increase in the relative amount of predominately one type
of TAG, SLOW-TAG (S-TAG), which can be produced _in vitro_
by the methods here described from the serum of patients
with malignant tumours, is the basis of the serum
diagnostic test described in the examples which follows.

EXAMPLE I

Production of Crude ASTROCYTIN-Precursor-Containing
Fraction.

Human brain glioma tumour tissue, removed at
surgery, is dissected so as to be as free as possible
of surface blood vessel and normal brain tissue. For
a typical amount of dissected tumour tissue of 11 grams,
the tissue is weighed into six 1.5 g and two 1.0 g
aliquots. Each aliquot is then treated as follows.

Each aliquot is homogenized in neutral buffer
solution by sonification or other mechanical means.
For example, each aliquot is homogenized in 100 cc per g
of tissue of 0.005 M phosphate buffer solution, pH 7,
in a Waring blender. Homogenization should be done
in the cold to prevent denaturaing of proteins. For

-18-

example, the blender should be precooled in a cold room at 0-5°C and operated for about only three minutes.

The homogenate is then centrifuged for clarification,

5 for example at 80,000 times gravity for 30 minutes in a refrigated ultracentrifuge. The soluble supernatant material is decanted and kept in the cold. The insoluble residue is rehomogenized with a further 100 cc of neutral buffer and centrifuged as before, and the

10 second soluble extract is combined with the first. The best yields are obtained when this procedure of homogenization and centrifuging is repeated until less than 50 micrograms of protein per ml. of solution are obtained in the supernatant. With most tissue, this

15 is accomplished by the fifth extraction.

The solutions thus obtained are combined and concentrated by pre-evaporation with subsequent dialysis, as by dialysis against 0.006 M phosphate buffer in the cold to produce a volume of 15 ml. The volume of this

20 solution is noted, an aliquot is taken for total protein analysis, and the remainder is fractionated to obtain the protein fraction having a pK range between 1 and 4. The preferred method of fractionation is chromatography as follows.

25 The solution is fractionated in the cold room (4°C) on a DEAE cellulose (Cellex-D) (trade mark) column 2.5 x 11.0 cm., which has been equilibrated with 0.005 M sodium phosphate buffer. Stepwise eluting solvent changes are made with the following solvents

30 (solutions): Solution (1) 4.04 g. NaH_2PO_4 and 6.50 g. Na_2HPO_4 are dissolved in 15 litres of distilled H_2O (0.005 molar, pH 7); Solution (2) 8.57 g NaH_2PO_4, is dissolved in 2480 ml of distilled H_2O; Solution (3) 17.1 g of NaH_2PO_4 is dissolved in 2480 ml of distilled H_2O; (0.05 molar,

35 pH 4.7); Solution (4) 59.65 g of NaH_2PO_4 is dissolved in

2470 ml distilled H_2O (0.175 molar); Solution (5) 101.6 g of NaH_2PO_4 is dissolved in 2455 ml distilled H_2O (0.3 molar, pH 4.3); Solution (6) 340.1 g of NaH_2PO_4 is dissolved in 2465 ml of distilled H_2O (1.0 molar, pH 4.1); and Solution (7) 283.64 g of 80% phosphoric acid (H_3PO_4) is made up in 2460 ml of distilled H_2O (1.0 molar, pH 1.0).

Add nervous tissue extract, 6 to 10 ml volume. Let it pass into the column. Then overlay with Solution (1) and attach a reservoir of 300 ml of Solution (1) to drip by gravity onto the column. Three ml aliquots of effluent are collected by means of an automatic fraction collector. The subsequent eluting solutions are exchanged stepwise at the following elution tube numbers. Solution (2): at tube 88, bring solution on column to top of resin, then overlay and attach reservoir of 50 ml of Solution (2); Solution (3): at tube 98, bring solution on column to top of resin, then overlay and attach reservoir of 75 ml of Solution (3); Solution (4): at tube 114, bring solution on colmn to top of resin, then overlay and attach reservoir of 150 ml of Solution (4); Solution (5): at tube 155, bring solution on column to top of resin, then overlay and attach reservoir of 125 ml of solution (5); Solution (6): at tube 187, bring solution on column to top of resin, then overlay and attach reservoir of 175 ml of Solution (7); continue eluting until, at tube 260, elution is complete. Use freshly prepared resin for every new volume of tissue extract. Each effluent tube is quantitatively analysed for protein. The elutes in tube numbers 212 to 230 are combined, and contain the crude products from which ASTROCYTIN will be produced.

While data have been published on this crude material, called fraction 10B in the past, [Protein

-20-

Metabolism of the Nervous System, pp 555-69 (Pleum Press, 1970); Journal of Neurosurgery, Vol. 33, pp 281-286 (September, 1970)], the clevage from fraction 10B of the specific product herein called ASTROCYTIN has now been accomplished. Crude fraction 10B can be prepared as a product in amounts between 0.1 and 10 mg per gm of original fresh nervous system tissue from which it was obtained. In addition to an ASTROCYTIN-precursor it contains varying amounts of covalently bound carbohydrate residues including a number of hexoses, namely glucose, galactose and mannose; hexosamines, including glucosamine, glactosamine and mannosamine; and occasionally other sugars, such as fructose, ribose and perhaps rhamnose. It also contains large molecular weight protein products, several lipids and nucleic acids.

EXAMPLE 2

Production of Purified ASTROCYTIN from Crude ASTROCYTIN-Precursor-Containing Fraction.

The ASTROCYTIN-Precursor-Containing Fraction is further isolated from contaminants. In the preferred embodiments, the material from Example 1 is chromato-graphed on Sephadex G-50 (trade mark) resin with a typical column of 40 cm length, 2.5 cm diameter, and 196 ml volume. The pressure used is 40 mm. Hg; the flow rate is 35ml per hour, and the buffer is 0.05 molar phosphate buffer solution, pH 7.2. The first (flow through) peak contains ASTROCYTIN-Precursor together with impurities, whereas subsequent peaks contain only impurities.

In the preferred embodiment, the products in the above first flow-through peak are then concentrated on Sephadex G-15 (trade mark), then passed onto a column of Cellex-D (trade mark) with the same solutions (1) to (7) as in Example 1, and the same elution steps

as are performed in Example 1. The product
ASTROCYTIN is present as a sharp peak in the same
tubes (numbers 212-230) as before, thus maintaining
its behaviour on Cellex-D (trade mark) chromatography
5   without the presence of a large number of contaminants.

Low molecular weight contaminants may then be
removed by techniques known to the art, such as millipore
disc filtration. In the preferred method, the product
ASTROCYTIN is freed of salt and other small molecular
10 weight contaminants by filtration through Millipore
Pellicon Disc No. 1000, 13 mm., which retains
substances of molecular weights greater than 1000 and
permits to pass through those of molecular weight
below 1000. The product ASTROCYTIN remains on the
15 Pellicon Disc, and is recovered therefrom by washing with
Solution (1) of Example 1.

ASTROCYTIN is then obtained by isolating the
compound having a molecular weight of about 8000 from
the above solution. A preferred method uses thin layer
20 gel (TLG) chromatography as follows:

The apparatus used is the commercially available
one designed by Boehringer Mannheim GmbH; Pharmacia
Fine Chemicals and CAMAG (Switzerland). The resin,
2.5 g. of Sephadex G-200 (trade mark) superfine, is
25 prepared in 85 ml of 0.5 M NaCl in 0.02 M $Na_2HPO_4KH_2PO_4$
Phosphate Buffer, pH 6.8 (6.6-7.0). Allow to swell for
two or three days at room temperature with occasional
gentle mixing (magnetic and other stirrers should not
be used). The swollen gel is stabilized for three
weeks at refrigerator temperature; however, bacterial
30 and fungal growth may interfere with the swollen gel.
If the gel is to be kept for longer periods of time,
a small amount of a bacteriostatic agent should be added
(e.g. sodium azide: 0.02%). 2.5 g of dry gel are used
to make two 20 x 20 cm glass plates 0.5 mm thick. The
35

plates are allowed to dry at room temperature for 10
minutes and transferred to a moist chamber where they
can be stored for about two weeks, or they are used
immediately after appropriate pre-equilibration
5 (usually, during the night, for a minimum of 12 hours).
The main function of equilibration is to normalize the
ratio between the stationary and mobile phase volumes.
With the pre-equilibrated plates in a horizontal
position, the substances to be determined are applied
10 with micropipettes as spots or as a streak at the start
line. 10 ml to 20 ml of 0.2-2% protein solution are
placed on the edge of a microscopic cover slide (18 mm
by 18 mm) and are held against the gel surface. In a
few seconds, the solution will soak into the gel. All
15 samples are first prepared on the cover slides and then
quickly applied. If not enough material is used, it
is difficult to locate individual spots after separation.
If too much material is applied, no defined separation
occurs. The samples are diluted with buffer for easier
20 handling and the separation of samples is carried out
in a descending technique with the plate at an angle
of 22°. The flow rate of about 1-2 cm/hour is most
suitable. Marker substances (such as cytochrome C,
haemoglobin, myoglobin or Bromophenol Blue labelled
25 albumin) are applied at different positions across
the plate and also to serve as reference proteins
for the calculation of the relative distance (mobility)
of unknowns. After the application of the samples,
the plates are replaced in the apparatus and the paper
30 wick is pushed slightly downwards to ensure good contact
with the gel layer. The paper wick must not drip.
Excess moisture is wiped off. The liquid solvent in
the reservoir is kept constant at 1 cm from the upper
end of the vessel. The runs are usually completed in
from 4 to 7 hours depending on the progress of the
35

separation. With coloured substances, separation follows directly. The separated spots of protein are easily made visible by transferring them to a paper sheet replica of TLG plate after the chromatographic

5 separation has been completed, and by staining them on the prewashed methanol + H_2O + acetic acid - 90:5:5, for 48 hours. The paper sheet is 3 mm. filter paper. As sheet of paper 20 x 18 cm is placed over the gel layer and pressed (rolled) just enough to

10 ensure contact with the gel. Care is taken not to trap air under the paper (replica) and not to disturb the gel layer. The liquid phase is soaked off from the gel layer by the paper and removed after about one minute, immediately dried in an oven at 60° temperature for

15 15 minutes, and stained in the normal way with any of the routine staining procedures. Staining is performed by spraying the replica-paper with 0.03% diazotized sulphanilic acid in 10% sodium carbonate (Pauley's Reagent). Staining can also be accomplished with a

20 saturated solution of Amido Black in methanol-acetic Acid (90:10v/v is used); the staining time is 5-10 minutes. For destaining, rinse with two volumes of the 90:10 methanol and acetic acid solution mixed with one volume of H_2O. It is difficult to obtain low background

25 staining without very extensive washing. The plates themselves may also be dried at about 60°C (in an oven with air circulation) but only if the ASTROCYTIN is to be stained. For isolation purposes, the plate should only be air dried at room temperature. Over-heating

30 can lead to cracking, but this can usually be avoided with 50°C - 60°C temperature which dries a Sephadex G-200 (trade mark) plate in 15-30 minutes. The dry plates are allowed to swell for 10 minutes in a mixture of methanol + H_2O + acetic acid (75:20:5), stained in

35 a saturated Amido Black in the same solvent system for

five hours, and subsequently washed by bathing for
two hours in the same solvent before they are dried.
For molecular weight determinations, the distance from
the starting line to the middle of each zone is

5   measured with an accuracy of 0.05 mm. either directly
on the print (replica) or on the densitogram. The
result is expressed by the R_m value defined as the ratio
of the migration distance of the tested protein (d_p)
to that of cytochrome C or myoglobin (d_m) which is

10   used as the reference protein.

The formula:

$$(-R_m = \frac{d_p}{d_m})$$

15   relates to the migration distance of the tested substance
to standard.

A straight calibration line is obtained by plotting
the logarithm of the molecular weight of the standards
used against the R_m. From this line, the molecular

20   weight of the unknown protein can be obtained. For
most exact results, mix equal parts of the protein
sample solution with the standard, in this case,
Cytochrome C, before applying to the plate. By the
above TLG procedure, the product ASTROCYTIN is

25   observed as a discrete spot at a distance of approximately
0.83 = 0.02, with reference to the standard Cytochrome
C, yielding an approximate molecular weight of 8000 for
ASTROCYTIN. Several discrete products are separated
by this procedure from ASTROCYTIN on the basis of slight

30   differences in molecular weight. Thus, three products
carried as contamination to this point with molecular
weights of approximately 64,000, 148,000 and 230,000
respectively, and one occasionally of molecular weight
32,000, have been detected and removed by the TLG methods

35   described above. The product ASTROCYTIN is aspirated with

-25-

the gel in which it is contained, in dry form, dissolved in Solution (1) and freed of resin by centrifuging or other similar means.

The product ASTROCYTIN which has been produced
5   at this stage is soluble in distilled water, soluble at neutral and acid pH, insoluble at alkaline pH and has a spectrophotometric absorption peak wave-length of 280 mμ. It is a polypeptide with molecular weight, as stated above, of approximately 8000. Its covalently
10   limked aminoacids are shown by hydrolysis with 6N HCl followed by quantitative automatic determination to have the following average composition of aminoacids:

	Approximate Number of residues
15 Aspartic acid	9
Threonine	5
Serine	6
Glutamic acid	13
Proline	4
20 Glycine	6
Alanine	9
Valine	4
1/2 Cysteine	2
Methionine	1
25 Isoleucine	2
Leucine	8
Tyrosine	2
Phenylalanine	3
Lysine	8
30 Histidine	2
Arginine	4
Approximate Total	88

35 - Cysteic acid, hydroxyproline, norleucine, ammonia,

-26-

isodesmosine, desmosine, hydroxyysine, lysinonorleucine and gamma-aminobutyric acid are all absent in detectable amounts, but a trace of glucosamine may be present.

5   From 11 grams of the starting brain tumour tissue in EXAMPLE 1, approximately 3 mg of purified ASTROCYTIN are produced by the above methods.

EXAMPLE 2A

PRODUCTION OF "REELER" RECOGNIN

10   Reeler disease is a genetic disorder in which animals fail to achieve stable coordinated motor activity, producing a reeling state, due to the failure of migration of certain nerve cells to a particular place in the brain, the cerebellum, at a particular

15 developmental time. Particular glial cells have been shown, in electron microscopic studies, to provide the vertical pole-like axes along which the nerve cells migrate to their new positions in the normal state. The failure of nerve cells to climb these glial fibers,

20 in Reeler disease is thought to be due to some disturbance in the nerve cells or the glia or both.

     Following the methods of Examples 1 and 2, Recognin from mouse reeler brain was produced and compared with Recognin produced from normal mouse

25 brain. The molecular weight of the Recognin produced from all areas of normal mouse brain was 8,000. The molecular weight of "Reeler" Recognin was 3,600 to 5,000. "Reeler" Recognin is abnormal, as shown by its much smaller molecular weight. Furthermore, the amount

30 of Recognin which can be produced from the cerebellum of reeler mouse brain is much reduced when compared with the normal. This is shown in Table I, as follows:

0015755

TABLE I

Recognin Concentration in Mouse Brain mg/g

	Normal	Reeler
5 Cerebellum (16-day od mouse)	2.50	0.71
Cortex (16-day old mouse)	0.60	0.96
Cortex (4-day old mouse)	0.29	0.53
Brainstem (16-day old mouse)	0.90	1.64
Whole Brain (17-day old mouse)	1.27	1.53
10 Whole Brain (1-day old mouse)	5.00	5.86

Table I shows that while there is a marked decrease in the concentration of Recognin in the cerebellum of Reeler mouse, there are the same or greater amounts of Recognins in other areas of the brain. The Recognin may not move from the other areas of the brain to the cerebellum, or the slight increase in other areas of the Reeler brain may reflect some compensatory action.

This pathological Recognin in Reeler brain is correlated with the inability for migrating brain cells to make the contacts they must in order to achieve proper placement, confirming the role of RECOGNINS in recognition and learning in cells.

By analogy, the ANTI-RECOGNINS to Recognin produced from mouse reeler brain may be produced and used in mice in a manner similar to the uses of ANTI-ASTROCYTIN and ANTI-MALIGNIN, as described herein.

EXAMPLE 3

Production of MALIGNIN-Precursor in Artifical Cancer Cell Culture Fermentations.

Generally, a sterile technique is scrupulously maintained.

All solutions (e.g. Hank's Balanced Salt (BSS), F-10 Nutrient medium, foetal calf serum and trypsin solution) are incubated at about 35°C in a water bath

for approximately 20 minutes or more before use.

Cells are removed from glioma tumour tissue and
grown in vitro for many generations using a suitable
medium, such as described below. Pre-rinse beakers are
5   used with a sterilizing solution, for example 12-
proponal plus amphyl or creolin solution.

In the preferred embodiment, the artificial cancer
cells (i.e., cells grown in vitro for many generations)
are grown in 250 ml flasks. The liquid medium in which
10   the cells are growing is discharged into the pre-rinsed
beakers. The cells are then washed gently with
5-10 ml of Hank's BSS or other similar solution for
about 30 seconds, agitation is avoided. All walls
and surfaces are washed. The solution is clarified of
15   cells by centrifuging in the cold for 10 to 20 minutes
at 3,000 rpm. The medium is poured into a beaker as
above. A small amount of buffered proteinase enzyme
solution is added and the medium is rinsed quickly
to avoid digestion of the cells. In the preferred method,
20   1-2 ml of trypsin solution (EDTA) are added and rinsing
is for only 10 seconds . The trypsin solution is poured
off.

A similar volume of fresh trypsin solution is added
and the medium is incubated until the cells are seen through
25   microscopic observation to be separated from the walls of
the chamber. This usually requires 5-10 minutes. A
suitable growth medium. such as 50 ml of a solution
of a 7-10 percent solution of foetal calf serum in 100 ml
of F-10 Nutrient medium is added.

30   Twenty-five ml of the fresh medium with cells are
transferred to a new growth chamber for propagation.
Both chambers are placed in an incubator at 35°C for
approximately seven days. by the procedure of this
Example to this point, an artificial cancer cell culture
35   is divided into two fresh cultures approximately every

seven days. This entire procedure may be repeated as often as desired, at approximately seven-day intervals, for each growth chamber. Thus, the number of cells growing _in vitro_ may be doubled approximately every seven days.

The cells may be extracted for the production of MALIGNIN after approximately seven days growth. For example, cells growing in each 250 ml growth chamber as described above, may be recovered as follows.

The medium is transferred to a centrifuge tube and centrifuged at 3,000 rpm in the cold for 10 minutes. The medium is discarded. The cells remaining in the growth chamber are scraped from the chamber walls and washed into the centrifuge tubes with a neutral buffer solution. The cells are washed twice with neutral buffer solution and centrifuged again at 3,000 rpm in the cold, and the medium is discarded. The washed cells are suspended in 10 ml of neutral phosphate buffer until ready for extraction of crude MALAGNIN-Precursor-Containing fraction.

EXAMPLE 4

Production of Crude MALIGNIN-Precursor-Containing Fraction.

Washed cells suspended in neutral buffer from Example 3 are mechanically disrupted under conditions which avoid the denaturing of most proteins. In the preferred method, the washed cells are treated in the cold with a sonifier for 20 seconds.

After sonification, the cell residues are centrifued at 30,000 rpm for 30 minutes and the supernatant material is decanted off. Ten ml aliquots of buffer solution are used to wash remaining cell residues. These are sonified and centrifuged as above and the supernatants are combined. The process is then repeated one more.

The combined supernant is pre-evaporated to reduce the approximate 30 ml volume to about 6-7 ml. An aliquot is taken for total protein analysis and the remainder is fractionated according to the methods

5   of EXAMPLE 1 for ASTROCYTIN Precursor.

EXAMPLE 5

Production of Purified MALIGNIN Product from Crude MALIGNIN-containing Fraction.

The product MALIGNIN is further isolated from

10   contaminants by the methods of EXAMPLE 2 for ASTROCYTIN.

In the TLG step of the preferred embodiment, the product MALIGNIN is observed as a discrete spot at a distance of approximately 0.91 ± 0.02 with reference to the standard cytochrome C, yielding an approximate

15   molecular weight of 10,000 for MALIGNIN.

The product MALIGNIN which has been produced at this stage is soluble in distilled water, soluble at neutral or acid pH, and insoluble at alkaline pH, and has a spectrophotometric absorption peak of 280 mµ. It is

20   a polypeptide with a molecular weight of approximately 10,000.

The molecular weights of MALIGNIN produced in fermentation cultures stabilized in successive generations of the cultures as shown by the thin layer

25   gel chromatography determinations are set forth in Table II (below). The reproducibility of the molecular weight determinations is remarkable in view of the inherent limitations of TLG chromatography.

TABLE 11

Reproducibility of Molecular weight of Malignin produced

Run No.	Mol. Wt	Run No	Mol Wt	Run No	Mol Wt
1	9,500	9	10,100	17	10,180
2	8,900	10	10,180	18	10,190
3	10,000	11	10,180	19	10,190
4	10,050	12	10,180	20	10,180
5	10,100	13	10,180	21	10,000
6	10,000	14	10,050	22	9,500
7	10,150	15	10,180	23	10,180
8	12,500	16	10,190		

MALIGNIN'S covalently linked aminoacids are shown by hydrolysis with 6N HCl followed by quantitative determination to have the following average composition of aminoacids:

	Approximate Number of Residues
Aspartic acid	9
Threonin	5
Serine	5
Glutamic acid	13
Proline	4
Glycine	6
Alanine	7
Valine	6
1/2 Cysteine	1
Methionine	2
Isoleucine	4
Leucine	8
Tyrosine	3
Phenylalanine	3

	Approximate Number of Residues
Lysine	6
Histidine	2
Arginine	5
Approximate Total	89

The amino acids cysteic acid, hydroxyproline, norleucine, ammonia, isodesmosine, desmosine, hydroxylysine, lysinonorleucine and gamma-aminobutyric acid are absent in detectable amounts.

A typical yield of pure MALIGNIN from twelve 250 ml reaction chambers of EXAMPLE 3 together is approximately 1 mg of MALIGNIN.

EXAMPLE 5A

Production of RECOGNIN L

Malignant cells grown in tissue culture, a lymphocytic lymphoma line of cells designated P_3J, were obtained from the Mason Research Institute, Rockville, Maryland, U.S.A.

Approximately 1 gm of packed cells of each of these were not further propagated upon receipt but extracted immediately and the Recognin produced according to the identical protocol used for producing Malignin from glioma cells (EXAMPLES 3, 4 and 5). Thus, the entire medium plus cells was transferred to centrifuge tubes with cold 0.005 M phosphate buffer, at pH 7, and centrifuged at 3,00 rpm in the cold for 10 minutes, the medium was discarded, the cells were washed twice with cold buffer and centrifuged again twice as before, and the washings were discarded. The washed cells were suspended in the same buffer and disrupted by sonification for 20 seconds. The cell residues were centrifuged at 30,000 rpm for 30 minutes, the solubilized protein in the supernatant material was decanted and collected, and the cell residues were

sonified twice more, until no further appreciable protein was solubilized. The solubilized protein was concentrated and the recognin was cloven and purified by Cellex D (trade mark) (BioRad) and Sephadex 200
5 (trade mark) (Pharmacia) gel chromatography. The yield, molecular weight, aminoacid composition, behaviour on thin layer gel chromatography and immunological properties of this polypeptide were similar to those of Astrocytin and Maligin. The yield in the case
10 of P_3J cells approximately 1 mg/g wet weight of cells.

The covalently linked aminoacids of Recognin L are shown, by hydrolysis (_in vacuo_) with 6N HCL at 108°C for 12 hours, followed by quantitative aminoacid
15 determination, to have the following average composition of amino acids (the nearest integer for the mole number of each amino acid is the average of two separate determinations):

	Number of Residues
Threonine	5
Serine	5
1/2 Cysteine	1
Methionine	1
Valine	6
Isoleucine	4
Phenylalanine	3
Lysine	6
Histidine	2
Arginine	5
Aspharitic Acid	8
Glutamic Acid	10
Leucine	7
Tryosine	1
Proline	5
Glycine	13
Alanine	10
Approximate Total	92

20

25

30

35

EXAMPLE 5B

Production of RECOGNIN M

Malignant cells grown in tissue culture, a mammary carcinoma cell line designated MCF-7, were obtained from

5 the Mason Research Institute, Rockville, Maryland.

Approximately 1 gm of packed cells of MCF-7 was not further propagated upon receipt but extracted immediately and the Recognin produced according to the protocol used for producing Malignin from glioma

10 cells (EXAMPLES 3, 4 and 5). Thus, the entire medium plus cells was transferred to centrifuge tubes with cold 0.005 M phosphate buffer, pH 7, and centrifuged at 3,000 rpm in the cold for 10 minutes, the medium discarded, the cells washed twice with cold buffer,

15 centrifuged again twice as before, and the washings discarded. The washed cells were suspended in the same buffer and disrupted by sonification for 20 seconds. The cell residues were centifuged at 30,000 rpm for 30 minutes, the solubilized protein in the supernatant

20 material was decanted and collected, and the cell residues were sonified twice more, until no further appreciable protein was solubilized. The solubilized protein was concentrated and the recognin was cloven and purified by Cellex D (trade mark) (BioRad) and

25 Sephadex 200 (trade mark) (Pharmacia) gel chromatography. The yield, molecular weight, aminoacid composition, behaviour on thin layer gel chromatography and immunological properties of this polypeptide are similar to those of Astrocytin and Malignin, the previous two

30 cancer recognins described. The yield in the case of MCF-7 cells was approximately 1 mg/g wet weight of cells.

The covalently linked aminoacids of Recognin M are shown, by hydrolysis (in vacuo) with 6N HCL at 108°C

35 for 12 hours followed by quantitative automatic

determination, to have the following average composition
of aminoacids (the nearest integer for the mole number of
each aminoacid is the average of two separate
determinations):

5

	Number of Residues
Threonine	5
Serine	5
1/2 Cysteine	1
Methionine	1
Valine	6
Isoleucine	4
Phenylalanine	3
Lysine	6
Histidine	2
Arginine	5
Aspartic Acid	9
Glutamic Acid	11
Leucine	8
Tryosine	2
Proline	4
Glycine	9
Alanine	9
Approximate Total	90

The unique structure of MALIGNIN, ASTROCYTIN,
RECOGNIN M and RECOGNIN L were confirmed by an exhaustive
computerized search which compared their compositions
with virtually all known protein substances.

The aminoacid composition of MALIGNIN and ASTROCYTIN
in terms of the absolute and relative amounts of each
aminoacid component based on the total number of
aminoacid residues per mole, and the absolute and
relative amounts of each aminoacid component in terms
of the molecular weight of the molecule, were submitted

0015755

-36-

to matrix computer analysis against the largest known
library of protein structures in the worl , i.e., that
of the National Biomedical Research Foundation,
Washington, D.C., U.S.A.. No structure identical to,

5   or even very close to, that of ASTROCYTIN, MALIGNIN,
RECOGNIN M or RECOGNIN L was found to the matrix analysis
comparison with several hundred thousand proteins and
protein fragments.

The only proteins that were structurally related

10 in any way are shown in Table III (below) with their
individual amino compositions and molecular weights for
comparison.- The computer is programmed to identify,
from the several hundred thousand possibilities, any.
degree of similarity in structure. Thus, for example,

15 proteins of molecular weight much larger or smaller will
not match, nor those with fewer than 85 or more than
95 residues, nor those with fewer than 10 or more than
15 glutamic acid residues, nor those with fewer than 6
or more than 11 aspartic residues, and so on for

20 each of the twenty aminoacids involved.

TABLE III

<u>COMPARISON BY COMPUTER SEARCH OF THE STRUCTURES</u>
<u>OF RECOGNINS WITH NEAREST STRUCTURES</u>

	Astro-cytin	Malignin	Recognin M	Recognin L	Cyto-chrome b5
Aspartic acid	9	9	9	8	9
Threonine	5	5	5	5	6
Serine	6	5	5	5	5
Glutamic acid	13	13	11	10	14
Proline	4	4	4	5	3
Glycine	6	6	9	13	6
Alanine	9	7	9	10	4
Valine	4	6	6	6	4
1/2 Cysteine	2	1	1	1	0
Methionine	1	2	1	1	1
Isoleucine	2	4	4	4	4
Leucine	8	8	8	7	7
Tyrosine	2	3	2	1	3
Phenylalanine	3	3	3	3	3
Lysine	8	6	6	6	7
Histidine	2	2	2	2	7
Arginine	4	5	5	5	3
Asparagine	0	0	0	0	0
Tryptophane	0	0	0	0	1
Glutamine	0	0	0	0	0
TOTAL NO. Residues	88	89	90	92	87
Molecular Weight	*8,000 (9,690)	*10,000 (10,067)	*8,000 (9,870)	*8,000 (9,606)	10,035

(By calculation)

* By thin layer gel chromatography

0015755

TABLE III   CONT/D........

	Ferre-doxin Luc. G1	Ferre-doxin Alf.	Acyl-Carrier E.Coli.	Neuro-physin Bovine	Neuro-physin Pig.	Gonad-otropin Releas.
Aspartic acid	10	8	7	2	3	0
Threonine	4	6	6	2	2	0
Serine	7	8	3	6	7	1
Glutamic acid	13	13	14	9	9	0
Proline	5	3	1	8	7	1
Glycine	7	7	4	16	14	2
Alanine	6	9	7	6	7	0
Valine	6	9	7	4	2	0
1/2 Cysteine	5	5	0	14	14	0
Methionine	0	0	1	1	1	0
Isolucine	4	4	7	2	2	0
Leucine	10	6	5	6	7	1
Tyrosine	3	4	1	1	1	1
Phenylalanine	3	2	2	3	3	0
Lysine	5	5	4	2	2	0
Histidine	1	2	1	0	0	1
Arginine	2	1	1	7	5	1
Asparagine	0	1	2	3	2	0
Tryptophane	1	1	0	0	0	1
Glutamine	4	3	4	5	4	0
TOTAL NO. Residues	96	97	77	97	92	10
Molecular Weight*	10,493	8,509				

This 'fingerprint' thus has some 22 individual variables to match. Some substances will match on one, on four or on five variables but none matches on all 22. In fact, none matches in better than 14 variables leaving differences in 8 variables.

Thus, the closest fit is cytochrome b_5 (human). As seen in Table III, the alanine, arginine, asparagine, aspartic acid, systeine, flutamine, histidine, methionine and tyrosine and tryptophane residue numbers all differ from appreciably to markedly from the Recognins. Because cytochrome b_5 contains 7 histidines while Astrocytin, Malignin, Recognin L and Recognin M contain only 2, they could not possibly have the same chemical structure.

The most unusual thing about the composition of Astrocytin, Malignin, Recognin L and Recognin M is the high concentration of glutamic acid. One would expect to find only 5 or 6 residues in 89.

Other next-closest fits are the ferrodoxins of leucaene glauca and of alfalfa, respectively, but these also differ markedly in four and six aminoacids, respectively, and appreciably in two others, and in having 96 and 97 residues, respectively. The next-closest fit is the acylcarrier protein of E. Coli 26, but this also differs markedly in eleven aminoacids from Malignin, Astrocytin, Recognin L and Recognin M and has only 77 residues.

Some other brain proteins (neurophysin, bovine and pig, and gonadotropin releasing hormone) are listed in Table III to illustrate how much worse the match is for the remaining several hundred thousand protein fragments in the computer memory bank.

Respiratory proteins may contain metals and/or haeme components in their _in situ_ state, but the isolated protein fragment, e.g., for apocytochrome b_5 contains neither. Additional microanalysis of

Astrocytin and Malignin has shown them to be free of
iron, sulphur, phosphorus and magnesium (all below
0.01%), and the spectral characteristics show typical
absorption at 280 mμ. Upon recombination of haeme with
5 apoprotein, the typical absorption spectra between
400 mμ and 450 mμ are restored.

Despite the structural uniqueness of Astrocytin,
Malignin, Recognin L and Recognin M from all other
proteins and protein fragments, it is noteworthy and
10 perhaps of great importance that the closest structures
are those of respiratory proteins. It is well known
in the art that many important relationships can be
drawn from both a developmental genetic point of view
and from a functional point of view in the type of
15 structure represented. If the Recognins are new protein
products whose in situ structural equivalents represent
respiratory functions, and these proteins are related,
as is now shown, to malignancy, then an opening has been
found to solve one of the great puzzles of cancer that is:
20 how are the energetics satisfied for these voracious,
rapidly reproducing malignant cells?

Aside from the theoretical importance of this
discovery, the data above on the increase in the
percentage of Malignin in more malignant cells, and
25 the data provided below indicating that Anti-Malignin
now only attaches to a Malignin-like chemical grouping
of the cancer cell, but having so attached is cytotoxic
to the cells, come together meaningfully. If the
malignin-like in situ compounds in cancer cells are
30 respiratory proteins, since the Anti-Malignin products
of this invention attach preferentially to these
in situ compounds, then if functional respiratory groups
are involved in this attachment, it is easy to
understand how this results in death of the cancer cells.

The therapeutic possibilitites for the Anti-Malignins,
35

and other similar chemoreciprocals, are greatly strengthened by this structural information on Malignin and Astrocytin, as well as on the demonstrated relationship of the amount of Malignin to the degree of malignancy.

5   The molecular weights of the four recognins described with particularity herein, i.e., Astrocytin, Malignin, Recognin M and Recognin L, calculated from their amino-acid composition, are close to each other (see Table III above). Thin layer gel chromatography with

10   Sephadex G200 (trade mark) (Pharmacia) gave a molecular weight for both Recognin L and Recognin M of approximately 8,000, the same as that obtained with Astrocytin. Since the calculated molecular weight of Astrocytin, based upon quantitative aminoacid

15   analysis, is 9,690, the lower apparent molecular weight of 8,000 obtained on thin layer chrometography may be, as in the case of MCF-7 and P_3J, a function of the slighly lower net acidic charge of these three polypeptides as compared with that of Malignin. The

20   molar compositions of the constituent aminoacids of the four recognins are also in close agreement with each other and (as shown for computer comparison), different from those of all other knwon polypeptides. The fact that the only four polypeptides whose compositions

25   are remotely related are phylogenetially ancient anaerobic oxidation-reduction enzymes has led to the suggestion that this may be an important clue to the basis of the anaerobic advantage of malignant cells recognized for many years but whose basis has not previously been

30   defined. Whether the minor differences between the four cancer recognins represent significant structural differences is as yet unknown. The composition of nine of the seventeen aminoacids detected is seen to be identical for each of the three products from those

35   cells which were grown in tissue culture. The principal

differences between the compositions of Recognin M and
Recognin L when compared with that of Malignin, are a
decrease in aspartic acid, glutamic acid, leucine and
tyrosine, and an increase in proline, glycine and

5   alanine.

Despite these chemical differences, the four
recognins are, to the present, indistinguishable
immunologically in each mode tested: (1) each reacts
equally well on Ouchterlony double diffusion with

10   anti-maligin antibody; and (2) separate immobilized
(bound to solid support) antigen preparations of each
showed them to be approximately equal in their ability
to bind antibody from human serum regardless of the type
of cancer from which the patient suffered. Thus,

15   immobilized Recognin M was observed to bind antibody
from the serum of brain glioma patients as well as
did immobilized Malignin.

<div align="center">EXAMPLE 5C</div>

Demonstration of increased yield, degree of

20   malignancy, and proportion of Malignin, by the provision
of greater volume and surface area during fermentation.

Examples 3 to 5 were repeated using 1000 cc.
flasks instead of 250 cc flasks. All quantities of
reagents were increased threefold.

25   The yield of the product MALIGNIN after 7 days
growth of inoculum was increased almost two fold by
increasing the space available for malignant cell growth
from 250 cc to 1000 cc. Table IV (below) shows
the yield of total protein in mg and the MALIGNIN

30   produced as a percentage of said total protein for
successive generations of fermentation cultures
in each size flask. Using 250 cc flasks, the mean
total protein produced was 17.5 mg. Using 1000 cc
flasks, the mean total protein produced was 40.4 mg.

35   Surprisingly, as the amount of malignant cell growth
(degree of malignancy) was increased per seven-day

growth period by providing a greater space and surface
for cell growth, the amount of MALIGNIN produced,
as a percentage of total protein, increased from a mean

5   of 10.7 percent using 250 cc. flasks to a mean of 28.3
percent using 1000 cc flasks for a constant growth
period of seven days.

      The relationship between the proportion of MALIGNIN
produced, and the degree of malignancy (i.e., as a

10   function of the amount of malignant cell growth
in vitro in seven days, measured as total protein
produced) is shown in Fig. 1 of the accompanying
drawings.

TABLE IV

Improved Yields in Successive Generations
of Fermentation Culture Production of Malignin

Flask Size	Malignin, mg.	Total Protein, mg.	% Malignin
250 cc.	.33	6.4	5.1
"	.16	6.7	2.4
"	.21	8.9	2.4
"	1.3	26.3	4.8
"	1.4	21.6	6.4
"	2.6	17.9	14.4
"	1.8	16.4	10.7
"	1.3	13.4	9.8
"	2.0	17.8	11.3
"	2.3	18.9	12.0
"	2.1	19.4	10.8
"	1.6	13.8	11.6
"	2.2	15.1	14.6
"	4.4	21.6	20.4
"	3.3	14.0	23.2
"	2.2	23.0	9.7
"	2.1	23.2	9.0
"	2.8	22.3	12.5
"	2.4	18.9	12.7
"	2.4	24.5	9.8
Mean		17.5 mg.	10.7%

TABLE IV (contd.)

Flask Size	Malignin, mg.	Total Protein, mg.	% Malignin
1000 cc.	9.8	41.3	23.6
"	7.2	25.4	28.4
"	5.9	24.9	23.6
"	11.7	37.5	31.2
"	13.3	44.8	29.8
"	16.5	56.5	29.4
"	9.5	41.3	22.9
"	10.7	38.8	27.5
"	12.5	41.6	29.9
"	13.3	46.7	29.4
"	11.6	45.2	25.7
	Mean	40.4 mg.	28.3%

Fig. 1 shows that the increased flask size results in approximately trebled proportions of MALIGNIN product.

Fig. 1 also demonstrates a relationship between MALIGNIN and malignancy. The interrupted line represents an ideal linear relationship. This demonstrated relationship is clearly not trivial since the proportion of MALIGNIN present increases as the cells become more unrestrained (pathological) in their growth. The normal in situ Recognin function relates, as previously stated, to the contact inhibition of growth of cells. The more pathological the growth of the malignant cells, the less contact inhibition operates, and the more MALIGNIN becomes the predominant protein.

Example 5C demonstrates that the growth of artificial cancer cell culture in large size growth containers unexpectedly results in an increased proportion of MALIGNIN produced, that is, in an increase in the percentage of total protein produced which is MALIGNIN. As used in this application, a large size growth container means one in which the ratio of the container volume to the volume of total medium which cells utilize in accordance with the methods of Example 3 is greater than about 8:1, for example, for 7:1 to 10:1. Example 5C illustrates a ratio of about 8:1.

EXAMPLE 6

Production of TARGET Reagents from RECOGNINS.

ASTROCYTIN, prepared as in EXAMPLE 2 above, or MALIGNIN, prepared as in EXAMPLE 5 above, or Recognin M or Recognin L, is complexed with a carrier to produce TARGET reagent.

In the preferred embodiment, ASTROCYTIN or MALIGNIN or Recognin L or Recognin M the RECOGNIN (the procedure works in the same way for each), i.e. is dissolved in 0.15 M NaH_2PO_4 - citrate buffer, pH 4.0. A bromoacetyl-resin, for example bromoacetylcellulose (BAC) having 1.0 to

1.5 milliequivalents of Br per gram of cellulose, stored in
the cold, is prepared in 0.15 M NaH_2PO_4 buffer, pH 7.2.
The buffer is converted to pH 4 by pouring off the pH 7.2
buffer solution and adding 0.15 M NaH_2PO_3 - citrate buffer,
pH 4.0. The RECOGNIN solution and the BAC solution are
stirred together (10.:1 BAC to RECOGNIN ratio) for 30
hours at room temperature, and then centrifuged.

It is preferred that all sites on the BAC which are
available to bind to RECOGNIN be bound. This may be
accomplished as follows. The supernatant material from
the immediately preceding step is lyophilized and the
protein content is determined to indicate the amount of
RECOGNIN not yet complexed to BAC. The complexed BAC-
ASTROCYTIN (or BAC-MALIGNIN) is resuspended in 0.1 M
bicarbonate buffer at pH 8.9, and stirred for 24 hours at
4° to permit the formation of chemical bonds between the
BAC and the RECOGNIN. After 24 hours, the suspension is
centrifuged and supernatant material is analysed for
protein. The complexed BAC-RECOGNIN is now resuspended in
0.05 M aminoethanol - 0.1 M bicarbonate buffer, pH 8.9, in
order to block any unreacted bromine. The suspension is
centrifuged, and the supernatant material is kept but not
analysed because of the presence of aminoethanol. The
removal of all unbound RECOGNIN is then accomplished by
centrifuging and resuspension for three washings in 0.15 M
NCl until no absorbence is measured on the spectrophoto-
meter at 266 mµ. The BAC-RECOGNIN complex is now stirred
in 8 M urea for 2 hours at 38°C, centrifuged, and washed
(three times usually suffices) with 8 M urea until no
absorbence is shown in the washings at 266 mµ. The
complex is then stirred at 37°C in 0.25 M. acetic acid for
2 hours to demonstrate its stability. The material is
centrifued and the absorbence of the supernatant material
is read at 266 mµ; no absorbence should be present. This
chemically complexed BAC-RECOGNIN is therefore stable and

can now be used as a reagent in the methods described
below; in this stable reagent form, it is referred to as
a synthetically produced complex whose physical and
chemical properties mimic the stable cell-bound precursor
5   of the RECOGNIN when it is in a potentially reactive state
with serum components. For storing, TARGET reagent is
centrifuged and washed until neutralized with 0.15 M
NaH_2PO_4 buffer, pH 7.2.

TARGET reagents may be prepared from bromoacetyl
10 liganded carriers other than cellulose, such as bromo-
acetylated resins or even filter paper.

EXAMPLE 7

Production of antisera to Astrocytin, Malignin, and
TARGET.

15 Antisera to Astrocytin, Malignin, or TARGET reagents
may be produced by inducing an antibody response in a
mammal. The following procedure has been found to be
satisfactory.

One mg. of RECOGNIN is injected into the toe pads of
20 white male rabbits with standard Freund's adjuvant, and
the same injection in then made intraperitoneally one week
later, again intraperitoneally the days later and, if
necessary, three weeks later. Specific antibodies may be
detected in the blood serum of these rabbits as early as
25 one week to ten days after the first injection. The same
procedure is followed for TARGET antigen by injecting that
amount of TARGET which contains 1 mg. of Astrocytin or
Malignin as determined by the Folin-Lowry determination
of protein.

30 The specific antibody to Astrocytin is named Anti-
Astrocytin. The specific antibody to Malignin is named
Anti-Malignin. Similarly, the specific antibody to
TARGET reagent is named Anti-Target.

These antibodies show clearly on standard Ouchterlony
35 gel diffusion tests for antigen-antibody reactions with

specific single sharp reaction lines produced with their specific antigen.

The presence of specific antibodies in serum can also be tested by the standard quantitative precipitin test for antigen-antibody reactions. Good quantitative precipitin curves are obtained and the micrograms of specific antibody can be calculated therefrom.

Further evidence of the presence of specific antibodies in serum can be obtained by absorption of the specific antibody Anti-Astrocytin onto Bromoacetyl-cellulose-Astrocytin (BAC-Astrocytin) prepared above. The antiserum containing specific Anti-Astrocytin can be reacted with BAC-Astrocytin. When the serum is passed over BAC-Astrocytin, only the specific antibodies to Astrocytin bind to their specific antigen Astrocytin. Since Astrocytin is covalently bound to Bromoacetyl-cellulose the specific antibody, Anti-Astrocytin, is now bound to BAC-Astrocytin to produce BAC-Astrocytin-Anti-Astrocytin (BACA-Anti-Astrocytin). This is proved by testing the remainder of the serum which is washed free from BAC-Astrocytin. On standard Ouchterlony diffusion, no antibodies now remain in the serum which will react with Astrocytin. It is therefore concluded that all specific antibodies (Anti-Astrocytin) previously shown to be present in the serum have been absorbed to BAC-Astrocytin. Furthermore, when Anti-Astrocytin is released from its binding to BAC-Astrocytin, it is thereby isolated so as to be free of all contaminating antibodies. This release of Anti-Astrocytin may be accomplished by washing the BACA-Anti-Astrocytin coupled with .25 M acetic acid (4°C., 2 hours) which has been shown above not to break the BAC-Astrocytin bond.

The antibodies to TARGET show clearly on standard Ouchterlony gel diffusion tests for antigen-antibody reactions with specific single reaction lines produced with TARGET which show a line of identity with the line of

reaction to ANTI-ASTROCYTIN or ANTI-MALIGNIN antisera (i.e. that produced in response to the injection of ASTROCYTIN or MALIGNIN itself). Some rabbits, it has been noted, have levels of ANTI-TARGET in their blood prior to

5 being injected with TARGET. These ANTI-TARGET substances, when reacted specifically with TARGET reagent as to be described in tests of human sera, lead to the production of approximately equivalent amounts of the two types of TAG, S-TAG and F-TAG (see later EXAMPLES).

10 **EXAMPLE 8**

Detection of Malignant Tumours by Quantitative Production _in_ _vitro_ of TARGET-ATTACHING-GLOBULINS (TAG) from Biological Fluids.

TARGET reagent prepared in accordance with EXAMPLE

15 6 is washed to remove any unbound RECOGNIN which may be present due to deterioration. The following procedure is satisfactory. TARGET reagent is stirred for two hours at 37°C with acetic acid and then centrifuged, the super-natant material is decanted, and the optical density of

20 the supernatant material is read 266 mμ. If there is any absorbence, this wash is repeated until no further material is solubized. The TARGET is then resuspended in phosphate buffered saline, pH 7.2 (Standard S-TAG and F-TAG purified from the previous reactions of human serum

25 by the procedure described below can be used if available, as reference standards to test the TARGET reagent, as can whole rabiit serum which has been determined to contain S-TAG and F-TAG by other TARGET preparations).

The Slow-Binding (S-TAG) determination is performed

30 as follows: Frozen serum stored for more than a few days should not be used. Serum is carefully prepared from freshly obtained whole blood or other body fluid by one of various standard procedures known in the art. The following procedure has been found to be satisfactory.

35 Blood is allowed to clot by standing for 2 hours at room

temperature in a glass test tube. The clots are separated
from the walls with a glass stirring rod, and the blood
is allowed to stand at 4°C for a minimum of 2 hours (or
overnight). The clots are separated from the serum by

5   centrifuging at 20,000 rpm and at 4°C for 45 minutes. The
serum is decanted into a centrifuge tube and centrifuged
again but this time at 2,000 rpm at 4°C for 45 minutes.
The serum is decanted and a 1% Solution of Methiolate
(1g. in 95 ml. water and 5 ml. of 0.2 M bicarbonate

10   buffer, pH 10) is added to the extent of 1% of the volume
and serum.

In duplicate determination, serum samples of 0.2 ml.
each prepared by the above or similar procedures, are
added to each of 0.25 ml. aliquots of TARGET suspension

15   reagent containing 100-200 micrograms of RECOGNIN per
0.25 ml. TARGET reagent. Each resulting suspension is
mixed at 4°C in such manner as to avoid pellet formation.
For example, a small rubber cap rapidly shaken may be used
for 1-2 seconds and, then, with the tubes slightly slanted

20   they may be shaken in a Thomas shaker for about 2 hours or
more. The TARGET reagent and the protein bound thereto
are separated from the serum. One procedure which has
been found to be satisfactory is as follows. The tubes
are centrifuged at 2,000 rpm for 20 minutes at 4°C, the

25   supernatant material is decanted, the pellet which is
formed by centrifuging is washed 3 times by remixing and
shaking at room temperature with 0.2-0.3 ml. of 0.15 M.
Saline, and centrifuged, and the supernatants are discarded.

The protein which remains attached to the TARGET is

30   cleaved therefrom and quantitatively determined. For
example, 0.2 ml. of 0.25 M acetic acid is needed, and the
suspension is shaken for 1 to 2 hours in a 37°C incubator.
The tubes are centrifuged at 2,000 rpm and at 4°C for 30
minutes. The supernatant material is carefully decanted

35   to avoid transferring particles and the optical density of
the supernatant is read at 280 mμ. The value of the

optical density is divided by a factor of 1.46 for results in micrograms per ml of serum protein (S-TAG). Duplicate determinations should not vary by more than 5%. Any other procedure effective for determining protein content

5 may be used, such as a Folin-Lowry determination, but standards must be specified to determine the range of control and tumour values of S-TAG minus F-TAG concentration.

The Fast-Binding (F-TAG) determination is performed

10 as follows: Frozen serum stored for more than a few days should not be used. Serum is carefully prepared from freshly obtained whole blood or other body fluid by standard procedures in the art. The procedure given above in this EXAMPLE for serum preparation is satisfactory.

15 Serum samples, prepared by the above or like procedures, are allowed to stand at 4°C for 10 minutes less than the total time the S-TAG serum determinations were allowed to be in contact with TARGET reagent above [e.g. 1 hour 50 minutes if a "two hour" S-TAG determination was

20 made]. This procedure equilibrates the temperature histories of S-TAG and F-TAG determinations.

0.2 ml. samples of the temperature equilibrated serum were added to each of 0.25 ml. aliquots of TARGET suspension reagent containing 100-200 micrograms of

25 RECOGNIN per 0.25 ml. of TARGET reagent, in duplicate determination. The suspension is then mixed at 4°C for approximately 10 minutes in such manner as to avoid pellet formation. For example, a small rubber cap rapidly shaken may be used for 1-2 seconds, and then, with the

30 tubes slightly slanted, they may be shaked in a Thomas shaker for approximately 10 minutes. The TARGET reagent and protein bound there to are separated from the serum. One procedure which has been found to be satisfactory is as follows. The tubes are then centrifuged at 2,000 rpm

35 for 20 minutes at 4°C, the supernatant is decanted, and the

pellet which is formed by centrifuging is washed 3 times
by remixing and shaking at room temperature with 0.2-0.3
ml. of 0.15 M Saline, further centrifuging is carried out
and the supernatants are discarded.

5   The protein which remains attached to the TARGET is
cleaved therefrom and quantitatively determined. The
procedure described above in this EXAMPLE for determining
S-TAG concentration is satisfactory. Various other
procedures effective to determine protein content may be

10   used, e.g. a Folin-Lowry determination, but standards must
be specified to determine the range of control and tumour
values of S-TAG minus F-TAG concentration.

The final results are expressed as TAG micrograms
per ml. of Serum, and equal S-TAG minus F-TAG. TAG values

15   in non-brain-tumour patients and other controls currently
range from zero (or a negative number) to 135 or 140
micrograms per ml of serum. In any result over 100 µg/ml,
a repeat determination is indicated. Some other tumours
may yield high TAG values, especially if secondary

20   (metastic) tumours are present in the brain. TAG values
in brain tumour patients currently range from 136 to 500
or more micrograms per ml of serum. In the first "blind"
study of 50 blood samples conducted according to the
procedures of this EXAMPLE utilizing TARGET reagent pre-

25   pared from Astrocytin and bromoacetylcellulose, 11 of 11
brain tumours and 28 of 32 normals were correctly
identified. One of the 4 supposed normals (i.e. non-
brain tumour controls) turned out to have a cancer of the
thyroid gland which had apparently been successfully trea-

30   ted some years before. The three remaining normals were
individuals aged 60-70 who were in poor health, possibly
having non-diagnosed cancer. Of the remaining 7 samples,
three out of three cases of Hodgkin's Disease were
correctly identified; one sample in the tumour range

35   (136-500 µg. TAG/ml.) corresponded to a patient having a

severe gliosis, and three samples in the non-tumour range
(0-135 µg. TAG/ml) corresponded to patients having
respectively an intercranial mass diagnosis uncertain but
non-tumour, and osteosarcoma (non-brain tumour) and a
melanotic sarcoma (non-brain tumour).

A subsequent study was conducted according to the
procedure of this example utilizing TARGET reagent prepared
from MALIGNIN and malignant brain tumours and all normals.

A still further study conducted according to the
procedure of this example extended the total number of
human serum specimens tested from 50 to 114. The utility
of these products and procedures is demonstrated in Table
V which below records the results of these tests. (see
EXAMPLE 13 for results on 290 specimens determined blind.

0015755

TABLE V

Normals*				Malignant Brain Tumours, Primary
Serum TAG μg/ml	Serum TAG μg/ml	Serum TAG μg/ml	Serum TAG μg/ml	Serum TAG μg/ml
124	19	54	65	459
113	55	27	113	397
105	51	41	130	236
130	82	21	79	137
127	44	27	61	298
38	127	21	123	397
100	31	0	14	241
125	0	14	20	241
30	125	62	41	217
250[1]	118	38	34	147
39	89	93	93	127
363[1]	99[6]	21	48	185
4	13[2]	0	20	253
31	270[3]	120	82	253
42	7	16	20	565
34	58	20	55	277
76	24	113	0	137
48	62	72		78[13]
85	89			138
	89			650
				160

Malignant Other Tumours, Brain Secondaries	Malignant Other Tumours, No Brain Secondaries	Uncertain Cerebrial Diagnosis
Serum TAG μg/ml	Serum TAG μg/ml	Serum TAG μg/ml
270	36[4]	165[9]
257	31[5]	144[9]
188	42[14]	13[9]
205	288[14]	209[10]
157[7]		75[10]
		184[11]
		27[11]
		110[12]
		192[15]

TABLE V (cont/d....)

* Includes normals, non-tumour medical and sugical
disorders. 1-very ill; undiagnosed, 2-Extra brain
intracranial mass, undiagnosed, 3-Marked gliosis,
4-Malignant melanoma, 5-Osteosarcoma, 6-Brain cyst
fluid, 7-Adenocarcinoma of colon, 8-Gastrectomy,
9-Headaches, 10-Emphysema, 11-Polymyalgia, 12-
Colon cancer, 13-Convulsions, 14-Cancer of pros-
trate, secondaries to bone, 15-Clinically "normal",
18-Months earlier, when this abnormal serum TAG
obtained: Now developed severe headaches, loss of
smell and taste.

EXAMPLE 9 -

Diagnosis of Tumour Cells by Immunofluorescence

The compounds Anti-Astrocytin, Anti-Malignin and
S-TAG have been shown to attach preferentially to tumour
cells. The specificity permits the use of these compounds
to diagnose tumour cells in histology sections by conju-
gating dyes or radioactive substances to Anti-Astrocytin,
Anti-Malignin or S-TAG. Standard labelling techniques may
then be used. A procedure using S-TAG is as follows.

One procedure which has been found satisfactory is a
modified St. Marie Procedure. Human brain tumour speci-
mens are frozen and 5 micron-thick sections are cut. They
are stored in a moist container at minus 70°C for from
4 to 8 weeks before staining. The conjugate may be a
standard antiserum such as a goat anti-rabbit conjugate.
The conjugate is labelled by techniques known in the art
with a fluorescent or other labelling substance.
Fluroescein labelled goat anti-rabbit conjugate as
commercially available may be used. The fluorescent
technique used was a standard one in which a 1:200 to
1:400 solution of TAG was incubated for about 30 minutes or
more on the tumour section, followed by washes to remove
unattached TAG. Three washes with phosphate-buffered

saline were found satisfactory. Conjugate incubation
with fluorescein-labelled conjugate followed by washes was
then performed, followed by microscopic inspection.
Normal cells and their processes failed to stain both in
5 tumour sections and in control sections of normal non-
tumour brain. Fluorescence was brightly present in tumour
glial cells and their processes.

EXAMPLE 10

Demonstration that Anti-Astrocytin, Anti-Malignin and
10 S-TAG are Cytotoxic to Tumour Cells Growing in Tissue
Culture.

Standard tests for determining cytoxicity may be
used. Generally, the number of cells in a fixed counting
chamber, usually arranged to contain about 100 live cells,
15 are counted. These cells are then treated with the agent
being tested and the number of cells which are still alive
is determined.

In a standard test of cytotoxicity of S-TAG Solution
obtained in accordance with the methods of EXAMPLE 8
20 against cells in tissue culture derived from a patient
with a glioblastoma Grade III-IV, well characterized as of
glial origin, S-TAG produced the death of all cells in the
counting chamber even when in a high dilution of 1:100
and 1:1000, representing as little as 0.2 and 0.02 ug.
25 of S-TAG per ml of solution. Similar results were obtained
with high dilutions of Anti-Astrocytin and Anti-Malignin.

Both the specificity exhibited in EXAMPLE 9 and the
cytotoxicity demonstrated in EXAMPLE 10 are highly
relevant to the therapeutic possibilities of Anti-
30 Astrocytin, Anti-Malignin and S-TAG for brain tumours in
man. These therapeutic users are in addition to the
practical diagnostic potential of both of these phenomena
for tumour tissue removed at operation but requiring
diagnosis by histology already demonstrated herein.

35 ### EXAMPLE 11

Hydrolytic Cleavage of RECOGNINS

A solution of RECOGNIN, in this case either Astrocytin or Malignin at a pH between 1 and 2 is allowed to stand in the cold. After 7 to 14 days, TLG chromato-

5 graphy shows the product to have been reduced in molecular weight by approximately 200. When the solution is allowed to stand longer, further units of approximately 200 molecular weight are cleaved every 7 to 10 days. Thus, with Astrocytin, the molecular weight is reduced from

10 8,000, and, with MALIGNIN, the molecular weight is reduced from 10,000, in each case by units of approximately 200, sequentially.

The physiochemical specificities of Astocytin are retained by each product down to approximately 4,000

15 molecular weight. The physiochemical specifities of Malignin are retained by each product down to approximately 5,000 molecular weight. This is shown by Ouchterlony gel diffusion tests against Anti-Astrocytin and Anti-Malignin, respectively.

20 This cleavage can also be accomplished enzymatically, as with trypsin and other proteinases, with similar results.

The molecular weights of these compound prepared by hydrolytic cleavage of RECOGNINS may be approximately

25 defined by the following formulae:

For products having the physiochemical specific-ites of Astrocytin: $400 + 200 x = Y$

For products having the physiochemical specifici-ties of Malignin: $5000 + 200 x = Y$,

30 wherein Y is the molecular weight of the product and X is 0 or an integer from 1 to 19.

EXAMPLE 12

Production of Artificial Tissue or Organ with RECOGNINS

35 A rigid walled tube of plastic, metal, or other

suitable rigid material is dipped into or impregnated with a highly concentrated [i.e., 10 mg./ml.],viscous solution of RECOGNIN, in this case, either Astrocytin or Malignin, until all surfaces are fully coated with the

5   RECOGNIN.   Alternately, RECOGNIN solution is passed through and around the tube under pressure until all surfaces are fully coated.   The tube is then dried in air or in vacuo, or lyophilized.   The process of coating is repeated several times in order to build up multiple

10   molecular layers of RECOGNIN coating.
        The tube is now ready to be placed in a cavity or in a tissue which contains Astrocytin or Malignin-like precursors in the neighboring tissue or fluid of a living mammal.   This artificial tissue or organ may be used to

15   minimize or to eliminate reactions which foreign substances without such RECOGNIN coating would incite.
        Artificial tissues or organs of other geometries may similarly be produced.
        EXAMPLE 13

20   Malignin is useful in a serum diagnostic test for the detection of a wide variety of tumours, including non-brain malignancies.   The results of determinations on individual sera, and remarks related thereto, are reported in the following table (Table VI)

TABLE VI
ANTI-MALIGNIN ANTIBODY DETERMINATION IN NON-BRAIN CANCERS
WITH MALIGNIN-BASED TARGET REAGENT.

Non-Brain (a) Malignancies	Number of Serums Studied	Number Abnor- mally Elevated	Number Border- line	Number in Normal Range
Carcinoma of:				
Lung	6	5		1
Breast (g)	10	10		
Colon (g)	7	7		
Rectum (g)	6	5		1
Prostate	2	2		
Bladder	1	1		
Ovary	4	2	1	1
Kidney	1	1		
Thyroid	1	1		
Undiffer- entiated	2	2		
Lymphoma	10	9		1
Hodgkins's Disease	6	5	1	
Multiple Myeloma	6	6		
Acute Myelogenous Leukaemia	2	2		
Chronic Myelogenous Leukaemia (b)	5	5		
Chronic Lymphocytic Leukaemia (c)	3	2	1	
Osteogenic Sarcoma	1			1
Melanotic Sarcoma	4	3	—	1
Total Non-Brain Malignancies	77	68	3	6
Brain Cancer (d,g)	85	80	1	4
Total Malignancies	162	148	4	10
Non-Malignant Medical and Surgical Disorders	51	3	-(e)	48
Normal	77	3	-(f)	74

0015755

Non-Brain (a) Malignancies	(c) % Elevated	% Elevated+ Borderline	Antibody Bound, as Protein Complexes in micrograms/ml Serum	
			S-TAG Mean ($\pm$S.D.)	Net TAG Mean ($\pm$S.D.)
Carcinoma of:				
Lung	83.3	83.3		
Breast (g)	100.0	100.0		
Colon (g)	100.0	100.0		
Rectum (g)	83.3	83.3		
Prostate	100.0	100.0		
Bladder	100.0	100.0		
Ovary	50.0	75.0		
Kidney	100.0	100.0		
Thyroid	100.0	100.0		
Undifferentiated	100.0	100.0		
Lymphoma	90.0	90.0		
Hodgkins's Disease	83.3	100.0		
Multiple Myeloma	100.0	100.0		
Acute Myelogenous Leukaemia	100.0	100.0		
Chronic Myelogenous Leukaemia(b)	100.0	100.0		
Chronic Lymphocytic Leukaemia (c)	66.6	100.0		
Osteogenic Sarcoma	0	0		
Melanotic Sarcoma	75.0	75.0		
Total Non-Brain Malignancies	88.3	92.2	482.5 ($\pm$202.8)	168.1 ($\pm$145.9)
Brain Cancer (d,g)	94.1	95.3	456.3 ($\pm$146.9)	183.4 ($\pm$116.3)
Total Malignancies	91.4	93.8		
Non-Malignant Medical and Surgical Disorders	5.9	–	259.8 ($\pm$115.8)	59.5 ($\pm$66.0)
Normal	3.9	–	280.3 ($\pm$79.5)	60.2 ($\pm$46.9)

Total Number 290; % correct = 91.4; 94.5% including borderline values.

Legend: S-TAG is the amount in micrograms per ml. of serum of antibody bound in 2 hours incubation; F-TAG is that bound in 10 minutes incubation; Net TAG = (S-TAG)-(F-TAG). Net TAG normal values: 0 to 134 micrograms per ml. serum. Elevated values: Net TAG 135 micrograms per ml. serum or above, or S-TAG greater than 400 micrograms per ml. even if a high F-TAG value results in Net TAG below 135 micrograms per ml. Borderline values: 100 to 134 micrograms per ml. The values for S-TAG were significantly different for Gps. 1 and 11 as compared with Gps 111 and 1V at a level of p below 0.000001 and for Net TAG at a level of p below 0.000001. All of these determinations were performed blind. Only those cases in which the clinical source of the serum was known, the clinical-pathological diagnosis established, and the serum received in good condition frozen in dry ice not longer than 48 hours from the time it was drawn are included in the study; 270 specimens had to be excluded on these bases.

(a) Seven of these determinations performed with Astrocytin-based TARGET reagent: 1 cancer of colon, 1 cancer of thyroid, 3 Hodgkins's Disease, 1 osteogenic sarcoma, 1 melanotic sarcoma.

(b) polycythemia vera,

(c) Terminal cases: 1 leukaemia excluded, some additional may also be excluded.

(d) Eleven of these determinations performed with Astrocytin-based TARGET reagent.

(e) Six cases originally borderline, then normal when repeated; one sickle cell anaemia in crisis with renal insufficiency, 1 case of obesity; 1 of gout.

(f) Eleven cases originally borderline, then normal when repeated.

(g) Two cases of breast cancer, 1 of rectum and 1 of brain demonstrated normal values of serum TAG and 2 colon cancer, borderline values, on serial determination during course of cancer treatment.

EXAMPLE 14

Detection of Non-Brain Malignant Cells
With Fluorescent Signal From TAG

The uses of TAG products coupled with a signal emitter such as a dye or a radioactive label to detect cancer cells has been described at various occurrences above. In this EXAMPLE, the detection of non-brain malignant cells is described.

As described in EXAMPLE 8 utilizing human serum, in the determination of TAG, after the anti-malignin antibody was bound to the immobilized antigen and non-bound serum proteins washed away, the antibody was cloven from the binding with 0.25 M acetic acid at 37°C for 2 hours and the TARGET reagent was separated therefrom by centrifuging. The TAG antibody solution was quantified by means of its absorption at 280 mµ. The TAG solutions were stored at -20°C, then thawed and combined, brought to pH 7 by titration with 6N NaOH, dialysed against phosphate-buffered saline of pH 7, filtered and concentrated on Millipore Pellicon 1000 (Trade Mark) membranes, centrifuged to clear insoluble protein and the immune globulin complexes, concentrated and freed of immunologically non-active compounds by Cellex D (trade mark) and Blue Sepharose CL6B (trade mark) (Pharmacia) chromatography. This human anti-malignin antibody reacts with anti-human gamma globulin in Ouchterlony double diffusion. When TAG is used with flourescein conjugated to anti-human gamma globulin in standard double layer Coons immunofluorescence, it stains malignant glia, breast carcinoma, ovarian carcinoma, adenocarcinoma of the colon, and other types of cancer cells in postoperative and biopsy tissue sections, as well as in human sputum, bronchial washings, pleural effusion fluid, gastric aspirate and

bladder urine. The concentration of protein in TAG
which yields clear fluorescence when the controls are
negative is from 1 to 10 ug per section.

The production of a "purified" TAG was undertaken
by reacting the sera from patients with a variety of
cancers with Bromoacetylcellulose - MALIGNIN by methods
earlier described (EXAMPLE 8). The antibody bound in
this reaction was cleaved with 0.25 M acetic acid,
quantified by measurement at O.D. 280 using a conversion
factor of 1.46 for gamma globulin, frozen and stored
at -20°C. This antibody was found to contain immuno-
globulin as determined by anti-human gamma-globulin anti-
serum specific for gamma chains (BioRad Laboratories,
Inc.) and with anti-FAB and anti-Fc fragments (Miles
Laboratories). It also reacts with rabbit anti-human
albumin (BioRad Laboratories).

It was found that, whereas 10 to 50 micrograms of
protein TAG are required to produce specific immuno-
fluorescent staining of cells which contain Malignin,
only 1 to 10 micrograms of purified protein TAG are
required for this specific staining in all sections,
and, in a few, less than one microgram has been found to
suffice.

It was found that the most active preparation of
purified TAG is that which is eluted with the highest
ionic strength elution, i.e., from 0.15 M to 1.5 M.
Any method of production which uses this fact is useful;
three preferred methods are given below.

Method 1 - Fractionation of TAG by chromatography
with DEAE cellulose (Cellex D, trade mark BioRad Labo-
ratories) was first employed with step-wise elution with
increasing ionic strength and decreasing pH, the same
sequence of eluants as that given in Example 1 for the
production of Crude Astrocytin-Precursor-Containing
Fraction. Good separation was obtained of the bulk of

the protein into three fractions, Peak 1 being obtained
with Solution 1 (see Example 1) and Peak 11 being obtained
with Solution 6 and Solution 7. Ouchterlony double dif-
fusion showed the TAG in Peak 1 still to contain appre-
5   ciable protein with albumin mobility, and, while Peak
11 contained most of the albumin, appreciable IgG could
be detected. Rechromatography of Peak 1 gave a pro-
gressively pure IgG until, after the seventh chroma-
tography, essentially no albumin (less than 3%) could
10   be detected by Ouchterlony gel diffusion in which 5 to
10 micrograms of human albumin were detectable with
rabbit anti-human albumin. The IgG so obtained was prone
to denaturing and loss of immunological reactivity after
a few days standing at 0-5°C.

15   Method II- A second fractionation of TAG was made
with chromatography on Sepharose CL-6B (trade mark)
(Pharmacia Inc.) starting with low molarity buffer (0.0005
M phosphate) and proceeding in two steps of 0.15 M and
1.5 M to elute the balance of the protein. As with the
20   Cellex D, (trade mark), one passage was found to be
inadequate to separate, and recycling slowly improved
the product. Once again, the most active fraction vis-
a-vis anti-malignin antibody was in the 1.5 M fraction.

Method III - Chromatography with Sepharose CL-6B
25   (trade mark) next to the glass fritted disc and Cellex
D (trade mark) layered above the Sepharose proved to be
the most satisfactory method.

The graphical representation in Fig.1A of the draw-
ings shows the fractions obtained on chromatography of
30   TAG utilizing Method 111. After the first eluate of 200
mls., 50 ml. or smaller sub-fraction were collected.
The protein content of each eluate was determined by
the optical density at 280 mμ with a uniform factor of
1.46 based on gamma globulin used to convert to micro-
35   grams for calculating recoveries. The absolute amount

of protein requires correction in those fractions in
which there is appreciable albumin. The points at which
the stepwise solvent changes were made are indicated by
arrows. The subfractions are designated by Roman Numerals
5   1 to Vlll, inclusive.

The solvents corresponding to letters A-F at the
arrows were as follows:

A - 0.01 M TRIS (pH 7.2)
10   B - 0.05 M TRIS with 0.1M NaCl (pH 7.2)
C - PBS, 0.11 M NaCl (pH 7.2)
D - PBS, 0.165 M NaCl (pH 7.2)
E - PBS, 0.33 M NaCl (pH 7.2)
F - 0.05 M TRIS, 1.5 M NaCl (pH 7.2)

15

The following Table Vll shows the recoveries from
each fraction, a semi-quantitative determination in
each of the gamma-globulin and albumin in each, as well
as the activity of each fraction in the immunofluores-
20   cent staining of cancer cells (the plus sign indicates
reaction, zero no reaction and plus/minus reaction in
some cases).

0015755

TABLE V11

Fraction	1	11	111	1V	
Recovered µg	2,877	1,140	2,351	2,942	1,808
%	12.5	5.0	10.2	12.8	7.9
Immunodiffusion Against: Anti-human IgG. specific for gamma chains	+++	++	++	+	0
Anti-human albumin	+	+	+	++	+++
Anti-Fab	+	++	0	++	+
Anti-Fc	++	++	+	++	+
Immunofluorescence	±	±	±	±	±

Fraction	V1	V11	V111
Recovered µg %	2,230 9.7	2,125 9.3	7,477 32.6
Immunodiffusion Against: Anti-Human IgG. specific for gamma chains	+	++	+++
Anti-human Albumin	+++	+++	+++
Anti-Fab	0	++	++
Anti-Fc	0	+	0
Immunofluorescence	±	±	+++

EXAMPLE 9B

Detection of Cancer Cells With
Radioisotope Signal From TAG

5 In this Example, the feasibility of attaching a radioactive label to TAG is demonstrated. Second, the injection into animals of this radio-labelled TAG has been accomplished and shown to be safe and effective. Third, the radio-labelled TAG localized preferentially

10 in the cancer tissue when compared with normal tissue, thus indicating that the specificity previously demonstrated _in_ _vitro_ of the preference for cancer cells which is conveyed by the use of specific anti-Malignin TAG products is confirmed _in_ _vivo_.

15 The Labelling of TAG with 99m Technetium (^{99m}Tc)

Procedure for Labelling

1. Two preparations of TAG were used, here designated TAG-1 and TAG-2. TAG-1 and TAG-2 (con-

20   centration of each 0.4 mg/0.5ml) were added to separate sterile evacuated vials.

2. To each vial was added 0.1 ml of a stannous chloride solution (10mg $SnCl_2$. $2 H_2O$ in 100 ml of 0.01 N HCl). The vials were mixed for 3-4 minutes.

25

3. 0.1 ml. (6mCi) of ^{99m}Tc-pertechnetate (sodium salt) was added and mixed 2-3 minutes.

Procedure for determining labelling efficiency

Samples of the ^{99m}Tc-TAG-1 and ^{99m}Tc-TAG-2 were

30 tested for labelling efficiency by descending paper chromatography using Watman No. 1 paper with 85% methanol as the solvent. A similar study was done with Sodium Pertechnetate-^{99m}Tc which acted as a control.

After 2 hours, the papers were removed from the

35 chromatography tank and divided into two sections:

(1) 1 cm about the origin; (2) The remaining paper up to the solvent front. Each section was then counted in a gamma well scintillation counter and its content of radioactivity was determined (cpm).

Approximately 50 lambda were plated on each paper strip.

Procedures for Antigen-Antibody Reactions

A portion of the labelled solution was also plated on an Ouchterlony gel plate to determine its ability to react with malignin in the antigen-antibody reaction. After a 3 hour period, the resulting sharp reactive lines were removed from the gel and their content of radioactivity was measured. An equal portion of the gel not involved in the reaction was also removed and its content of radioactivity was also measured as background.

Results
Labelling Efficiency

TABLE 1
Labelling Efficiency of ^{99m}Tc-TAG-1 and ^{99m}Tc-TAG-2

COMPOUND	SITE ON PAPER	CPM
$NaTcO_4$ -99mTc	origin	4.94×10^5
$NaTcO_4$ -99mTc	solvent front	6.25×10^6
TAG-1	origin	4.35×10^6
TAG-1	solvent front	6.76×10^4
TAG-2	origin	1.96×10^6
TAG-2	solvent front	3.98×10^4

TABLE 1 (cont.)

COMPOUND	%	CHEMICAL SPECIES
$NaTcO_4$-99mTc	7.33%	Reduced TcO_4^-
$NaTcO_4$-99mTc	92.67%	TcO_4^-
TAG-1	98.47%	TAG-99mTc
TAG-1	1.53%	TcO_4^-
TAG-2	98.01%	TAG-99mTc
TAG-2	1.99%	TcO_4^-

TABLE 2 - ANTIGEN-ANTIBODY RESECTION

GEL AREA	COUNTS PER MIN	%
TAG-2 line	1.99×10^6	92.04%
Background gel	1.72×10^5	7.96%

Conclusions

The following conclusions were reached relative to the quality control tests employed:

1. ^{99m}Tc-pertechnetate was reduced by stannous chloride to a more reactive oxidation state (+4+5)

2. The reduced pertechnetate labelled both the TAG-1 and TAG-2 preparations.

3. The 99mTc-TAG-2 was tested for its ability to retain its activity and was found to retain its ability to react immunologically.

The Use of Radio-Labelled TAG in vivo to Detect Cancer Cells

Wistar rats were injected intracerebrally with Cisgliome tumour cells which had had previous passages in rats and in tissue culture. The rats were observed for

the first signs of growing tumour, such as weakness, tremor or unsteadiness. These symptoms first appear seven to 10 days from injection, and, with fast growing tumours result in death within three to four days in

5 many animals, and one week in all. As soon as symptoms appeared, the animals were injected with labelled TAG intravenously in the tail vein, then, the animal was anaesthetized at varying times, the brain was removed, the tumour dissected free of normal brain, and the radio-

10 activity in each dissected specimen was compared.

Preliminary ^{99m}Tc-TAG experiment

Animal	Sacrifice (hr. post injection)	Tumor wt.,mg.	Counts/gm/min.	
			Tumor	Normal Brain
A	1.25	1.9	149,100	13,400
B	5.30	6.0	16,200	6,600
C	7.21	23.9	53,000	5,800
D	24.10	29.0	66,700	7,500

Tumour and normal brain specimens were counted overnight in the gamma-well counter. All samples and

25 standards were decay corrected for convenience to the mid-count of the first sample in the sequence.

Conclusion

The preferential localization of radioactivity in tumour as compared with normal tissue is demonstrated

30 above.

CLAIMS

1. A process for the production of Recognin L which comprises extracting artificial lymphoma tumour cells grown in culture with a neutral buffer by repeated disruption of the tissue to solubilize protein fractions; separating from the resulting extract of solubilized proteins the fraction having a pK range of from about 1 to 4; and isolating therefrom a product having a molecular weight of about 8,000 (as determined by thin layer gel chromatography).

2. A process according to claim 1, wherein the separation step is carried out by adding said extract of solubilized proteins to a chromatographic column, and eluting with increasingly acidic solvents.

3. A process according to claim 1 to 2, wherein the isolation step is carried out by filtering the eluate to obtain a fraction containing Recognin L, and separating Recognin L therefrom by thin layer gel chromatography.

4. A product Recognin L prepared in accordance with the process of any of Claims 1 to 3, characterized by forming a single line precipitate with its specific antibody in quantitative precipitin tests and Ouchterlony gel diffusion tests; being soluble in water and aqueous solutions having an acid or neutral pH, and insoluble at an alkaline pH; having a spectrophotometric absorption peak wave-length of 280 mμ; and having a molecular weight of about 8,000 (as determined by thin layer gel chromatography).

5. Recognin L.

6. The product of claim 5 characterized by forming a precipitate with its specific antibody in quantitative precipitin tests and Ouchterlony gel diffusion tests; being soluble in water and aqueous solutions having an acid or neutral pH, and insoluble at an alkaline pH; having a spectrophotometric

absorption peak wave-length of 280 mμ; and having a molecular weight of about 8,000 (as determined by thin layer gel chromatography).

7. The product of claim 6, further characterized by having an amino acid composition approximately as follows:

	Approximate number of Residues
Aspartic Acid	8
Threonine	5
Serine	5
Glutamic Acid	10
Proline	5
Glycine	13
Alanine	10
Valine	6
1/2 Cystine	1
Methionine	1
Isoleucine	4
Leucine	7
Tyrosine	1
Phenylalanine	3
Lysine	6
Histidine	2
Arginine	5
Approximate Total	92

the amino acids cysteic acid, hydroxyproline, norleucine, ammonia, isodesmosine, desmosine, hydroxylysine, lysinonorleucine and gamma-aminobutyric acid being absent in detectable amounts.

8. The product of claim 7, further characterized by being capable of complexing with bromoacetylcellulose to form bromoacetyl-cellulose-Recognin L, and by producing the specific antibodies Anti-Recognin L upon injection into mammals, said Anti-Recognin L being toxic to tumour cells *in vitro* and producing fluorescence of

glioma cells when coupled with fluorescein.

9. A member selected from the class consisting
of Anti-Recognin L, Bromoacetylcellulose-Recognin L and
Bromoacetylcellulose-Recognin L-Anti-Recognin L.

10. A process for producing Recognin M which
comprises extracting artificial mammary tumour cells
grown in culture with a neutral buffer by repeated
disruption of the tissue to solubilize protein fractions;
separating from the resulting extract the fraction
having a pK range of about 1 to 4; and isolating there-
from the product having a molecular weight of about
8,000 (as determined by thin layer gel chromatography).

11. A process according to claim 10, wherein
the isolation step is carried out by adding said
extract of solubilized proteins to a chromatographic
column and eluting with increasingly acidic solvents.

12. A process according to claim 11, wherein
said isolation step is carried out by filtering the
eluate to obtain a fraction containing Recognin M and
separating Recognine M therefrom by thin layer gel
chromatography.

13. A product Recognin M prepared in accordance
with the process of claim 10 or claim 11, characterized
by forming a single line precipitate with its specific
antibody in quantitative precipitation tests and
Ouchterlony gel diffusion tests; being soluble in water
and aqueous solutions having an acid or neutral pH, and
insoluble at an alkaline pH; having a spectrophotometric
absorption peak wave length of 280 mμ; and having a
molecular weight of about 8,000 (as determined by thin
layer gel chromatography).

14. Recognin M.

- 15. The product of claim 14 characterized by forming a precipitate with its specific antibody in quantitative precipitin tests and in Ouchterlony gel diffusion tests; being soluble in water and aqueous solutions having an acid or neutral pH, and insoluble at an alkaline pH; having a spectrophotometric absorption peak wave length of 280 mμ; and having a molecular weight of about 8,000 (as determined by thin layer gel chromatography).

16. The product of Claim 15, further characterized by having an amino acid composition approximately as follows:

	Approximate Number of Residues
Aspartic Acid	9
Threonine	5
Serine	5
Glutamic Acid	11
Proline	4
Glycine	9
Alanine	9
Valine	6
1/2 /Cysteine	1
Methionine	1
Isoleucine	4
Leucine	8
Tyrosine	2
Phenylalanine	3
Lysine	6
Histidine	2
Arginine	5
Approximate Total	90

the amino acids cysteic acid, hydroxyproline, norleu-
cine, ammonia, isodesmosine, desmosine, hydroxylysine,
lysinonorleucine and gamma-aminobutyric acid being
absent in detectable amounts.

17. The product of Claim 16, further character-
ized by being capable of complexing with bromoacetyl-
cellulose to form bormoacetylcellulose-Recognin M, and
by producing the specific antibodies Anti-Recognine M
upon injection into mammals, said Anti-Recognin M being
toxic to tumour cells _in vitro_ and producing Fluore-
scence of tumour cells when coupled with fluorescein.

18. A member selected from the class consisting
of Anti-Recognin M, Bromoacetylcellulose-Recognin M and
Bromoacetylcellulose-Recognin M-Anti-Recognin M.

19. A process for producing a Slow-Target
Attaching Globuline (S-TAG) which comprises reacting
blood serum or other body fluid with Bromoacetyl-
cellulose-Recognin or Bromoacetylcellulose-Recognin L
for approximately two hours or more at a low temperature
to prevent degradative reactions, and treating the
resulting material with dilute acid to cleave S-TAG
therefrom.

20. A product S-TAG prepared in accordance with
the process of claim 19, said product being characterized
by being soluble in aqueous buffered solutions, forming
a single line precipitate with Recognin M or Recognin L
in Ouchterlony gel diffusion tests, being non-dialysable
in cellophane membranes, being retained by millipore
filters which retain molecules over 25,000 molecular
weight, having molecular weights in different states of
aggregation as determined by thin layer gel chromato-
graphy of approximately 50,000, and multiples thereof
into the macroglobulin range, and having a spectro-
photometer absorption peak wave-length of 280 mµ.

21. A process for producing Fast-Target-Attaching Globulin (F-TAG) which comprises reacting blood serum or other body fluid with Bromoacetylcellulose-Recognin M or Bromoacetylcellulose-Recognin L for approximately 10 minutes at a low temperature to prevent degradative reactions and treating the resulting material with dilute acid to cleave F-TAG therefrom.

22. A product F-TAG prepared in accordance with the process of claim 21, said product being characterised by being soluble in aqueous buffered solutions, forming a single line precipitate with Recognin M or Recognin L in Ouchterlonly gel diffusion tests, being non-dialysable in cellophane membranes, being retained by millipore filters which retain molecules over 25,000 molecular weight having molecular weights in different states of aggregation as determined by thin layer gel chromato-graphy of approximately 50,000, and multiples thereof into the macroglobulin range, and having a spectrophoto-meter absorption peak wave-length of 280 mμ.

23. A method of detecting cancer tumours in living mammals which comprises determining the concen-tration of S-TAG and F-TAG as claimed in any of claims 19 to 22 produced by a known volume of the mammal's blood serum or other body fluid.

24. The method of producing Bromoacetylcellu-lose-Recognin M or Bromoacetylcellulose Recognin L which comprises mixing Recognin M or Recognin L with Bromo-acetylcellulose in a manner adapted to form a complex.

25. The method of producing Bromoacetylcellulose-Recognin M-Anti-Recognin M or Bromoacetylcellulose-Recognin L-Anti-Recognin L which comprises reacting Anti-Recgonin M or Anti-Recognin L with Bromoacetylcellulose-Recognin M or Bromoacetylcellulose-Recognin L respectively in a manner adapted to form a complex.

26. The method of producing Anti-Recognin M or Anti-Recognin L, which comprises decomplexing Bromo-acetylcellulose-Recognin M-Anti-Recognin M or Bromo-acetylcellulose-Recognin L-Anti-Recognin L, respectively by hydrolytic treatment with an acid or with a protein-ase enzyme.

27. The method of producing Anti-Recognin M or Anti-Recognin L which comprises inducing in a mammal an antibody response to Recognin M or Recognin L, respectively.

28. A process for diagnosing the presence of tumour cells in a histology preparation, which comprises applying a member of the class consisting of fluores-ceinconjugated TAG and fluorescein-conjugated Anti-Recognin M or Anti-Recognin L to said preparation, whereby fluorescence occurs only in the tumour cells.

29. A process for increasing the yield of TAG products from a mammal which comprises injection of an immunologically effective dose of a member of the group consisting of Recognin M, Recognin L, Anti-Recognin M Anti-Recognin L and Recognin M and Recognin L complexed with carriers into said mammal.

30. In a process for producing Recognin M or Recognin L which comprises the production of a Recognin M or Recognin L Precursor in Artificial Cancer Cell Fermentation Culture, followed by production of crude Recognin M or Recognin L Precursor-Containing fraction, followed by production of purified RECOGNIN M or Recognin L product from crude Recognin-Containing fraction, the improvement which comprises the growth of artificial cancer cell fermentation culture in large size growth containers.

Amount of Malignin Produced as a Function of Degree of Malignancy.

Fig.1.

Fig.1A.